Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2021 | Aug. 05, 2021 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-40296 | |
Entity Registrant Name | NUVVE HOLDING CORP. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 86-1617000 | |
Entity Address, Address Line One | 2468 Historic Decatur Road, | |
Entity Address, City or Town | San Diego, | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 92106 | |
City Area Code | (619) | |
Local Phone Number | 456-5161 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 18,626,624 | |
Amendment Flag | false | |
Entity Central Index Key | 0001836875 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 | |
Current Fiscal Year End Date | --12-31 | |
Common Stock | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Trading Symbol | NVVE | |
Security Exchange Name | NASDAQ | |
Warrants | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants to Purchase Common Stock | |
Trading Symbol | NVVEW | |
Security Exchange Name | NASDAQ |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets | ||
Cash | $ 48,062,996 | $ 2,275,895 |
Restricted cash | 380,000 | 0 |
Accounts receivable | 1,138,649 | 999,897 |
Inventories | 4,217,131 | 1,052,478 |
Security deposit, current | 0 | 20,427 |
Prepaid expenses and other current assets | 2,174,347 | 416,985 |
Total Current Assets | 55,973,123 | 4,765,682 |
Property and equipment, net | 103,385 | 95,231 |
Intangible assets, net | 1,550,795 | 1,620,514 |
Investment | 670,951 | 670,951 |
Right-of-use operating assets | 5,253 | 0 |
Deferred financing costs | 43,818,000 | 0 |
Security deposit, long-term | 3,057 | 3,057 |
Total Assets | 102,124,564 | 7,155,435 |
Current Liabilities | ||
Accounts payable | 3,290,154 | 2,960,249 |
Accrued expenses | 2,283,634 | 585,396 |
Deferred revenue | 502,368 | 196,446 |
Debt | 0 | 4,294,054 |
Operating lease liabilities - current | 5,406 | 0 |
Other liabilities | 3,363 | 0 |
Total Current Liabilities | 6,084,925 | 8,036,145 |
Warrants liability | 1,183,000 | 0 |
Other long-term liabilities | 26,614 | 0 |
Total Liabilities | 7,294,539 | 8,036,145 |
Commitments and Contingencies - Note 14 | ||
Stockholders’ (Deficit) Equity | ||
Preferred stock, value, issued | 0 | 0 |
Common stock, $0.0001 par value, 100,000,000 and 30,000,000 shares authorized; 18,626,624 and 9,122,996 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively | 1,863 | 2,616 |
Additional paid-in capital | 126,816,249 | 19,650,659 |
Accumulated other comprehensive income (loss) | 18,762 | (77,841) |
Accumulated deficit | (32,006,849) | (20,457,823) |
Total Stockholders’ Equity (Deficit) | 94,830,025 | (880,710) |
Total Liabilities and Stockholders’ Equity (Deficit) | 102,124,564 | 7,155,435 |
Convertible Preferred Stock | ||
Stockholders’ (Deficit) Equity | ||
Preferred stock, value, issued | $ 0 | $ 1,679 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Preferred stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued (in Shares) | 0 | 0 |
Preferred stock, shares authorized (in Shares) | 1,000,000 | 1,000,000 |
Preferred stock, shares outstanding (in Shares) | 0 | 0 |
Common stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in Shares) | 100,000,000 | 30,000,000 |
Common stock, shares issued (in Shares) | 18,626,624 | 9,122,996 |
Common stock, shares outstanding (in Shares) | 18,626,624 | 9,122,996 |
Convertible Preferred Stock | ||
Preferred stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued (in Shares) | 0 | 16,789,088 |
Preferred stock, shares authorized (in Shares) | 0 | 30,000,000 |
Preferred stock, shares outstanding (in Shares) | 0 | 16,789,088 |
Aggregate liquidation preference | $ 0 | $ 12,156,676 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue | ||||
Total revenue | $ 981,330 | $ 463,143 | $ 1,780,362 | $ 1,408,473 |
Operating expenses | ||||
Cost of product and service revenue | 362,658 | 10,808 | 489,886 | 33,204 |
Selling, general, and administrative | 5,269,791 | 868,813 | 9,752,531 | 1,717,420 |
Research and development | 1,689,245 | 665,460 | 2,952,195 | 1,207,085 |
Total operating expenses | 7,321,694 | 1,545,081 | 13,194,612 | 2,957,709 |
Operating loss | (6,340,364) | (1,081,938) | (11,414,250) | (1,549,236) |
Other income (expense) | ||||
Interest income (expense) | 1,984 | (5,455) | (595,565) | (7,330) |
Change in fair value of conversion option on convertible notes | 0 | 3,107 | 0 | 0 |
Change in fair value of warrants liability | (351,602) | 0 | 70,228 | 0 |
Other, net | 503,676 | 31,184 | 391,561 | 5,656 |
Total other expense | 154,058 | 28,836 | (133,776) | (1,674) |
Loss before taxes | (6,186,306) | (1,053,102) | (11,548,026) | (1,550,910) |
Income tax (benefit) expense | 1,000 | 1,000 | 1,000 | 1,000 |
Net loss attributable to common stockholders | $ (6,187,306) | $ (1,054,102) | $ (11,549,026) | $ (1,551,910) |
Net loss per share attributable to common stockholders, basic (in Dollars per share) | $ (0.33) | $ (0.12) | $ (0.79) | $ (0.18) |
Net loss per share attributable to common stockholders, diluted (in Dollars per share) | $ (0.33) | $ (0.12) | $ (0.79) | $ (0.18) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares) | 18,668,009 | 8,778,916 | 14,560,862 | 8,778,916 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares) | 18,668,009 | 8,778,916 | 14,560,862 | 8,778,916 |
Products and services | ||||
Revenue | ||||
Total revenue | $ 766,516 | $ 54,325 | $ 1,078,419 | $ 360,046 |
Grants | ||||
Revenue | ||||
Total revenue | $ 214,814 | $ 408,818 | $ 701,943 | $ 1,048,427 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (6,187,306) | $ (1,054,102) | $ (11,549,026) | $ (1,551,910) |
Other comprehensive (loss) income | ||||
Foreign currency translation adjustments, net of taxes | (20,146) | (38,190) | 96,603 | (11,409) |
Comprehensive loss | $ (6,207,452) | $ (1,092,292) | $ (11,452,423) | $ (1,563,319) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($) | Total | Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit | Series A Convertible Preferred StockPreferred Stock |
Balances (in Shares) at Dec. 31, 2019 | 24,542,314 | 16,789,088 | |||||
Balances at Dec. 31, 2019 | $ 1,669,977 | $ 2,454 | $ 17,131,913 | $ 107,620 | $ (15,573,689) | $ 1,679 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Conversion of shares due to merger capitalization | 0 | $ (1,576) | 3,255 | 0 | 0 | $ (1,679) | |
Conversion of shares due to merger capitalization (in Shares) | (15,763,398) | (16,789,088) | |||||
Balances December 31, 2020, effect of reverse recapitalization (in Shares) | 8,778,916 | ||||||
Balances December 31, 2020, as previously reported | 1,669,977 | $ 878 | 17,135,168 | 107,620 | (15,573,689) | ||
Stock-based compensation | 17,557 | 17,557 | |||||
Currency translation adjustment | 26,781 | 26,781 | |||||
Net loss | (497,808) | (497,808) | |||||
Balances (in Shares) at Mar. 31, 2020 | 8,778,916 | 0 | |||||
Balances at Mar. 31, 2020 | 1,216,507 | $ 878 | 17,152,725 | 134,401 | (16,071,497) | $ 0 | |
Balances (in Shares) at Dec. 31, 2019 | 24,542,314 | 16,789,088 | |||||
Balances at Dec. 31, 2019 | 1,669,977 | $ 2,454 | 17,131,913 | 107,620 | (15,573,689) | $ 1,679 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Currency translation adjustment | (11,409) | ||||||
Net loss | (1,551,910) | ||||||
Balances (in Shares) at Jun. 30, 2020 | 8,778,916 | 0 | |||||
Balances at Jun. 30, 2020 | 139,636 | $ 878 | 17,168,146 | 96,211 | (17,125,599) | $ 0 | |
Balances (in Shares) at Mar. 31, 2020 | 8,778,916 | 0 | |||||
Balances at Mar. 31, 2020 | 1,216,507 | $ 878 | 17,152,725 | 134,401 | (16,071,497) | $ 0 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Stock-based compensation | 15,421 | 15,421 | |||||
Currency translation adjustment | (38,190) | (38,190) | |||||
Net loss | (1,054,102) | (1,054,102) | |||||
Balances (in Shares) at Jun. 30, 2020 | 8,778,916 | 0 | |||||
Balances at Jun. 30, 2020 | 139,636 | $ 878 | 17,168,146 | 96,211 | (17,125,599) | $ 0 | |
Balances (in Shares) at Dec. 31, 2020 | 0 | 26,162,122 | 16,789,088 | ||||
Balances at Dec. 31, 2020 | (880,710) | $ 0 | $ 2,616 | 19,650,659 | (77,841) | (20,457,823) | $ 1,679 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Conversion of shares due to merger capitalization | 0 | $ 0 | $ (1,704) | 3,383 | 0 | 0 | $ (1,679) |
Conversion of shares due to merger capitalization (in Shares) | 0 | (17,039,126) | (16,789,088) | ||||
Balances December 31, 2020, effect of reverse recapitalization (in Shares) | 9,122,996 | ||||||
Balances December 31, 2020, as previously reported | (880,710) | $ 912 | 19,654,042 | (77,841) | (20,457,823) | ||
Beneficial conversion feature - convertible debenture | 427,796 | 427,796 | |||||
Conversion of convertible debenture (in Shares) | 544,178 | ||||||
Conversion of convertible debenture | 3,999,435 | $ 54 | 3,999,381 | ||||
Repurchase of shares (in Shares) | (600,000) | ||||||
Repurchase of common stock from EDF | (6,000,000) | $ (60) | (5,999,940) | ||||
Assumption of private warrant liability from Newborn | (1,253,228) | (1,253,228) | |||||
Merger recapitalization, net of share redemption of issuance costs (in Shares) | 8,060,418 | ||||||
Merger recapitalization, net of share redemption of $18,629 and issuance costs of $5,979,675 | 51,751,363 | $ 806 | 51,750,557 | ||||
Issuance of common shares (in Shares) | 208,532 | ||||||
Issuance of common shares | 2,085,320 | $ 21 | 2,085,299 | ||||
PIPE offering, less issuance costs (in Shares) | 1,425,000 | ||||||
PIPE offering, less issuance costs of $2,500 | 14,247,500 | $ 143 | 14,247,357 | ||||
Notice of exercise of put option | (2,000,000) | (2,000,000) | |||||
Stock-based compensation | 262,105 | 262,105 | |||||
Currency translation adjustment | 116,749 | 116,749 | |||||
Net loss | (5,361,720) | (5,361,720) | |||||
Balances (in Shares) at Mar. 31, 2021 | 0 | 18,761,124 | 0 | ||||
Balances at Mar. 31, 2021 | 57,394,610 | $ 0 | $ 1,876 | 83,173,369 | 38,908 | (25,819,543) | $ 0 |
Balances (in Shares) at Dec. 31, 2020 | 0 | 26,162,122 | 16,789,088 | ||||
Balances at Dec. 31, 2020 | (880,710) | $ 0 | $ 2,616 | 19,650,659 | (77,841) | (20,457,823) | $ 1,679 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Currency translation adjustment | 96,603 | ||||||
Net loss | (11,549,026) | ||||||
Balances (in Shares) at Jun. 30, 2021 | 0 | 18,626,624 | 0 | ||||
Balances at Jun. 30, 2021 | 94,830,025 | $ 0 | $ 1,863 | 126,816,249 | 18,762 | (32,006,849) | $ 0 |
Balances (in Shares) at Mar. 31, 2021 | 0 | 18,761,124 | 0 | ||||
Balances at Mar. 31, 2021 | 57,394,610 | $ 0 | $ 1,876 | 83,173,369 | 38,908 | (25,819,543) | $ 0 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Additional merger recapitalization costs | (265,736) | (265,736) | |||||
Repurchase of shares (in Shares) | (134,500) | ||||||
Repurchase of common stock from EDF | 0 | $ (13) | 13 | ||||
Issuance of warranties to Stonepeak and Evolve | 30,234,000 | 30,234,000 | |||||
Issuance of options to purchase shares of common stock to Stonepeak and Evolve | 12,584,000 | 12,584,000 | |||||
Stock-based compensation | 1,090,603 | 1,090,603 | |||||
Currency translation adjustment | (20,146) | (20,146) | |||||
Net loss | (6,187,306) | (6,187,306) | |||||
Balances (in Shares) at Jun. 30, 2021 | 0 | 18,626,624 | 0 | ||||
Balances at Jun. 30, 2021 | $ 94,830,025 | $ 0 | $ 1,863 | $ 126,816,249 | $ 18,762 | $ (32,006,849) | $ 0 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) (Parenthetical) | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Statement of Stockholders' Equity [Abstract] | |
Merger recapitalization, net of share redemption | $ 18,629 |
Issuance costs | 5,979,675 |
Less issuance costs | $ 2,500 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Operating activities | ||
Net loss | $ (11,549,026) | $ (1,551,910) |
Adjustments to reconcile to net loss to net cash used in operating activities | ||
Depreciation and amortization | 81,874 | 82,280 |
Share-based compensation | 1,352,708 | 32,978 |
Beneficial conversion feature on convertible debenture | 427,796 | 3,242 |
Accretion of discount on convertible debenture | 116,147 | 0 |
Change in fair value of warrants liability | (70,228) | 0 |
Loss on disposal of asset | 1,381 | 0 |
Gain on extinguishment of PPP Loan | (492,100) | 0 |
Noncash lease expense | (1,003) | 0 |
Change in operating assets and liabilities | ||
Accounts receivable | (139,140) | 249,622 |
Inventory | (3,164,653) | 24,200 |
Prepaid expenses | (2,209,159) | (47,579) |
Accounts payable | 330,890 | 191,493 |
Accrued expenses | 1,595,165 | 14,690 |
Deferred revenue | 305,922 | 266,844 |
Net cash used in operating activities | (13,413,426) | (734,140) |
Investing activities | ||
Proceeds from sale of property and equipment | 7,969 | 0 |
Purchase of property and equipment | 0 | (22,504) |
Net cash provided by investing activities | 7,969 | (22,504) |
Financing activities | ||
Proceeds from issuance of convertible notes | 0 | 28,000 |
Proceeds from Newborn Escrow Account | 58,184,461 | 0 |
Redemption of Newborn shares | (18,629) | 0 |
Issuance costs related to reverse recapitalization and PIPE offering | (3,970,657) | 0 |
Proceeds from PIPE offering | 14,250,000 | 0 |
Repayment of Newborn sponsor loans | (487,500) | 0 |
Repurchase of common stock from EDF | (6,000,000) | 0 |
Newborn cash acquired | 50,206 | 0 |
Purchase of stock from investor | (2,000,000) | 0 |
Payment of financing costs | (531,527) | 0 |
Payment of finance lease Obligations | (1,989) | 0 |
Proceeds from PPP/EIDL Loan | 0 | 642,000 |
Issuance of Common Stock | 0 | (3) |
Repayment proceeds from shareholder loan | 0 | (75,000) |
Proceeds from shareholder loan | 0 | 75,000 |
Net cash provided by financing activities | 59,474,365 | 669,997 |
Effect of exchange rate on cash | 98,193 | (11,454) |
Net increase (decrease) in cash and restricted cash | 46,167,101 | (98,101) |
Cash and restricted cash at beginning of year | 2,275,895 | 326,703 |
Cash and restricted cash at end of period | 48,442,996 | 228,602 |
Supplemental Disclosure of Noncash Financing Activity | ||
Conversion of preferred stock to common stock | 1,679 | 0 |
Conversion of debenture and accrued interest to common shares | 3,999,435 | 0 |
Conversion of shares due to reverse recapitalization | 3,383 | 0 |
Issuance of common stock for merger success fee | 2,085,299 | 0 |
Non-cash merger transaction costs | 2,085,299 | 0 |
Accrued transaction costs related to reverse recapitalization | 189,434 | 0 |
Issuance of private warrants | 1,253,228 | 0 |
Forgiveness of PPP Loan | 492,100 | 0 |
Issuance of Stonepeak and Evolve warrants | 30,234,000 | 0 |
Issuance of Stonepeak and Evolve options | $ 12,584,000 | $ 0 |
Organization and Description of
Organization and Description of Business | 6 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business | Organization and Description of Business (a) Description of Business Nuvve Holding Corp., a Delaware corporation headquartered in San Diego, California (the “Company” or “Nuvve”), formerly known as NB Merger Corp., was founded on November 10, 2020 under the laws of the state of Delaware. On March 19, 2021, the Company (at the time known as NB Merger Corp.) acquired the outstanding shares of Nuvve Corporation (“Nuvve Corp.”), and the Company changed its name to Nuvve Holding Corp. (see Business Combination below). The Company owns 100% of Nuvve Corporation, a Delaware corporation headquartered in San Diego, California (“Nuvve Corp.”), which was founded on October 18, 2010, to develop and commercialize Vehicle to Grid ("V2G") technology. Nuvve has developed a proprietary V2G technology, including the Company’s Grid Integrated Vehicle (“GIVe ™ ”) cloud-based software platform, that enables it to link multiple electric vehicle ("EV") batteries into a virtual power plant ("VPP") to provide bi-directional energy to the electrical grid in a qualified and secure manner. The VPP can generate revenue by selling or making available to utility companies excess energy when the price is relatively high or buying energy when the price is relatively low. The V2G technology may allow energy users to reduce energy peak consumption and enable utilities to reduce the required internally generated peak demand. This V2G technology was initially developed in 1996 by Dr. Willett Kempton, Ph.D, at the University of Delaware and is now being deployed for commercial use as a part of the management of fleets of electric vehicles, including buses. Nuvve’s technology is patent protected. Nuvve’s first commercial operation was proven in Copenhagen in 2016. Since then, Nuvve has established operations in the United States, the United Kingdom, France, and Denmark. In addition to Nuvve’s algorithms and software, Nuvve provides complete V2G solutions to its customers, including V2G bidirectional chargers which are preconfigured to work with Nuvve’s GIVe platform. The Company’s technology is compatible with several charger manufacturers both in DC (such as CHAdeMO, a DC charging standard for electric vehicles, enabling seamless communication between the vehicle and the charger) and AC mode. (b) Structure of the Company Nuvve has one wholly owned subsidiary, Nuvve Corp. Nuvve Corp., has three wholly owned subsidiaries: (1) Nuvve Denmark ApS, (“Nuvve Denmark”), a company registered in Denmark, (2) Nuvve SaS, a company registered in France, and (3) Nuvve LTD, a company registered in United Kingdom. In March 2020, following the establishment of its investment in Dreev in 2019 (Note 5), the Company ceased operations of its subsidiary, Nuvve SaS in France. The two employees of Nuvve SaS resigned from the Company in March 2020 and were concurrently hired by Dreev. Financial results for Nuvve SaS are included in the Company’s financial results through the cessation of operations. On August 4, 2021, the Company formed a joint venture, Levo Mobility LLC with Stonepeak Rocket Holdings LP, a Delaware limited partnership and Evolve Transition Infrastructure LP, a Delaware limited partnership. Please see Note 15 for a summary description of the key items of the joint venture agreement. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies (a) Basis of Presentation The accompanying audited (i) condensed consolidated balance sheet as of December 31, 2020, which has been derived from audited financial statements, and (ii) the unaudited interim condensed financial statements have been prepared in accordance pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Therefore, it is suggested that these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Current Report on Form 8-K dated March 19, 2021, filed with the Securities and Exchange Commission. In the opinion on management, in addition to the adjustments to record the business combination (the “Business Combination”) between Newborn Acquisition Corp (“Newborn”), the Company, and Nuvve Corp., pursuant to which the Company acquired the outstanding shares of Nuvve Corp. (see paragraph below), the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, comprehensive loss, cash flows, and stockholders’ equity for the interim periods, but are not necessarily indicative of the results to be anticipated for the full year 2021 or any future period. The Business Combination between Newborn, a Special Purpose Acquisition Company (“SPAC”), the Company, prior to the Business Combination a wholly owned subsidiary of Newborn, and Nuvve Corp., prior to the Business Combination a privately held operating company, pursuant to which the Company acquired the outstanding shares of Nuvve Corp. (see Business Combination below) was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Newborn was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Nuvve Corp. issuing stock for the net assets of Newborn, accompanied by a recapitalization. The net assets recorded from Newborn are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Nuvve Corp. The shares and corresponding capital amounts and earnings per share available for common stockholders prior to the Business Combination have been retroactively restated to reflect the exchange ratio established in the Business Combination. (b) Principles of Consolidation The condensed consolidated financial statements include the accounts and operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation. (c) Business Combination The Company is party to a merger agreement (as amended, the “Merger Agreement”), dated as of November 11, 2020 and amended as of February 20, 2021, by and among Newborn, a Cayman Islands company, the Company, a Delaware corporation and prior to the Business Combination a wholly owned subsidiary of Newborn, Nuvve Merger Sub Inc., a Delaware corporation and prior to the Business Combination a wholly-owned subsidiary of the Company (the “Merger Sub”), Nuvve Corp., a Delaware corporation, and Ted Smith, an individual, as the representative of the stockholders of Nuvve Corp. On March 16, 2021, Newborn held an extraordinary general meeting of its shareholders, at which Newborn’s shareholders approved the Business Combination, along with certain other related proposals. On March 19, 2021 (the “Closing Date”), the parties consummated the Business Combination. Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i) Newborn reincorporated to the State of Delaware by merging with and into the Company, with the Company surviving as the publicly-traded entity (the “Reincorporation Merger”); and (ii) immediately after the Reincorporation Merger, Merger Sub merged with and into Nuvve, with Nuvve surviving as a wholly-owned subsidiary of the Company (the “Acquisition Merger”). Immediately prior to the effectiveness of the Reincorporation Merger and the Acquisition Merger, the Company filed its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, pursuant to which, among other things, the Company changed its name to “Nuvve Holding Corp.” and adopted certain other changes that the Company’s Board of Directors deemed appropriate for an operating public company. In connection with the entry into the Merger Agreement, on November 11, 2020, Newborn entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors (the “PIPE Investors”), under which, immediately before the closing of the Business Combination, the PIPE Investors purchased 1,425,000 ordinary shares of Newborn, at a purchase price of $10.00 per share, for an aggregate purchase price of $14,250,000 (the “PIPE”). The PIPE Investors also received warrants to purchase 1,353,750 ordinary shares of Newborn (the “PIPE Warrants”) that were identical to Newborn’s other outstanding warrants. Also, on November 11, 2020, Nuvve Corp. entered into a bridge loan agreement with an accredited investor, under which, on November 17, 2020, the investor purchased a $4,000,000 6% Senior Secured Convertible Debenture from Nuvve Corp. (the “Bridge Loan”), which automatically converted into shares of Nuvve Corp.’s common stock immediately before the closing of the Business Combination. Upon the closing of the Reincorporation Merger, each of Newborn’s outstanding units was automatically separated into its constituent securities, and Newborn’s outstanding securities (including the Newborn ordinary shares and Newborn warrants purchased by the PIPE Investors) were converted into a like number of equivalent securities of the Company, except that each of Newborn’s rights was converted automatically into one-tenth of one share of the Company’s common stock in accordance with its terms. Upon the closing of the Acquisition Merger, each share of Nuvve Corp.’s common stock outstanding immediately prior to the effective time of the Acquisition Merger (including the shares issued upon conversion of Nuvve Corp.’s preferred stock and upon conversion of the Bridge Loan as described above) automatically was converted into approximately 0.212403050 shares (the “Closing Exchange Ratio”) of the Company’s common stock, for an aggregate of 9,122,996 shares of the Company’s common stock. Each outstanding option to purchase Nuvve Corp.’s common stock (“Nuvve Options”) was assumed by the Company and converted into an option to purchase a number of shares of the Company’s common stock equal to the number of shares of Nuvve Corp.’s common stock subject to such option immediately prior to the effective time multiplied by the Closing Exchange Ratio, for an aggregate of 1,303,610 shares of the Company’s common stock, at an exercise price equal to the exercise price immediately prior to the effective time divided by the Closing Exchange Ratio. The Closing Exchange Ratio was determined by taking (i) a number of shares of the Company’s common stock equal to (A) the Closing Merger Consideration (as defined below), divided by (B) $10.00 per share, and dividing it by (ii) the sum of (x) the total number of shares of Nuvve Corp.’s common stock outstanding as of immediately prior to closing (including the shares issued upon conversion of Nuvve Corp.’s preferred stock, but excluding the shares issued upon conversion of the Bridge Loan) and (y) the total number of shares of Nuvve Corp.’s common stock issuable upon exercise of Nuvve Options outstanding immediately prior to the closing. The “Closing Merger Consideration” was determined by taking $100,000,000, subtracting the amount of Nuvve Corp.’s indebtedness for borrowed money as of the closing of the Acquisition Merger (excluding Payroll Protection Program loans eligible for forgiveness – see Note 7), which was zero, and adding the aggregate exercise price of the Nuvve Options outstanding as of the date of the Merger Agreement or granted prior to the closing of the Acquisition Merger, which was $4,265,785. Additionally, the former stockholders of Nuvve Corp. may be entitled to receive up to 4.0 million earn-out shares of the Company’s common stock if, for the fiscal year ending December 31, 2021, the Company’s revenue equals or exceeds $30,000,000. The former Nuvve Corp. stockholders will be entitled to a portion of the earn-out shares only if they continue to hold their shares of the Company’s common stock received in the Acquisition Merger through the earn-out payment date. Pursuant to a purchase and option agreement, dated as of November 11, 2020 (the “Purchase and Option Agreement”), between the Company and EDF Renewables, Inc. (“EDF Renewables”), a former stockholder of Nuvve Corp. and the owner of more than 5% of the Company’s common stock, immediately after the closing, the Company repurchased 600,000 shares of the Company’s common stock from EDF Renewables at a price of $10.00 per share. In addition, on the Closing Date, EDF Renewables exercised its option to sell an additional $2,000,000 of shares of the Company’s common stock back to the Company at a price per share of $14.87 (the average closing price over the five As agreed between the parties to the Merger Agreement, immediately following the closing of the Acquisition Merger, the Company’s board of directors consisted of seven directors, five of whom were designated by Nuvve and two of whom were designated by Newborn. A majority of the directors qualified as independent directors under rules of Nasdaq. In Newborn’s initial public offering, Newborn issued 5,750,000 units at $10.00 per unit. Each unit issued in the initial public offering consisted of one ordinary share, one warrant to purchase one-half of an ordinary share (the “Public Warrant”), and one right automatically convertible into one-tenth of an ordinary upon completion of an initial business combination. Concurrently with the initial public offering, Newborn sold to its sponsor 272,500 units at $10.00 per unit in a private placement. Each unit in the private placement consisted of one ordinary share, one warrant to purchase one-half of an ordinary share (the “Private Warrant”), and one right automatically convertible into one-tenth of an ordinary share upon completion of an initial business combination. Newborn received net proceeds of approximately $57,989,380 from the public and private units. Upon closing of the initial public offering and the private placement, $57,500,000 was placed by Newborn in a trust account with Continental Stock Transfer & Trust Company acting as trustee (the “Trust Account”). On the Closing Date of the Business Combination, the balance in the Trust Account was $58,471,961. After the closing of the Business Combination, and other transactions described above, including payment of $18,630 for redemptions of ordinary shares by Newborn stockholders, payment of transaction costs of $3,702,421, repayment of loans made by Newborn’s sponsor to Newborn of $487,500, repurchase of $6,000,000 in common shares held by EDF Renewables, and transfer into an escrow account with Silicon Valley Bank of $495,000 to cover the balance of the Company’s PPP Loan payable (Note 7), the Company received total net proceeds from the Trust Account in cash of $47,768,410. Also on March 19, 2021, the PIPE closed, and the Company received cash proceeds, net of $2,500 of transaction costs, of $14,247,500. (d) Emerging Growth Company Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits emerging growth companies (“EGC”) to delay complying with new or revised financial accounting standards that do not yet apply to private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act). The Company qualifies as an EGC. The JOBS Act provides that an EGC can elect to opt-out of the extended transition period and comply with the requirements that apply to non-EGCs, but any such election to opt-out is irrevocable. The Company has elected not to opt-out of such an extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This different adoption timing may make a comparison of the Company’s financial statements with another public company which is neither an EGC nor an EGC that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. (e) COVID-19 The novel coronavirus (COVID-19) which was declared a pandemic in March 2020, and the related restrictive measures such as travel restrictions, quarantines, and shutdowns, has negatively impacted the global economy. As national and local governments in different countries ease COVID-19 restrictions, and vaccines are distributed and rolled out successfully, we continue to see improved economic trends. However, COVID-19 and actions taken to mitigate its spread have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. The Company continues to monitor the situation closely but, at this time, is unable to predict the cumulative impact, both in terms of severity and duration, that the coronavirus pandemic has and will have on its business, operating results, cash flows and financial condition, and it could be material if the current circumstances continue to exist for a prolonged period of time. In addition to any direct impact on Nuvve’s business, it is reasonably possible that the estimates made by management in preparing Nuvve’s financial statements have been, or will be, materially and adversely impacted in the near term as a result of the COVID-19 outbreak. (f) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include the impairment of intangible assets, the net realizable value of inventory, the fair value of share-based payments, the fair value of notes payable conversion options, revenue recognition, the fair value of warrants, and the recognition and disclosure of contingent liabilities. Management evaluates its estimates on an ongoing basis. Actual results could materially vary from those estimates. (g) Warrants The Company reviews the terms of warrants to purchase its common stock to determine whether warrants should be classified as liabilities or stockholders’ equity in its consolidated balance sheet. In order for a warrant to be classified in stockholders’ equity, the warrant must be (a) indexed to the Company’s equity and (b) meet the conditions for equity classification in Accounting Standards Codification (“ASC”) Subtopic 815-40, Derivatives and Hedging – Contracts in an Entity’s Own Equity . If a warrant does not meet the conditions for equity classification, it is carried on the consolidated balance sheet as a warrant liability measured at fair value, with subsequent changes in the fair value of the warrant recorded in the statement of operations as change in fair value of warrants in other income (expense). If a warrant meets both conditions for equity classification, the warrant is initially recorded in additional paid-in capital on the consolidated balance sheet, and the amount initially recorded is not subsequently remeasured at fair value. (h) Foreign Currency Matters For Nuvve Corp., Nuvve SaS, and Nuvve LTD, the functional currency is the U.S. dollar. All local foreign currency asset and liability amounts are remeasured into U.S. dollars at balance sheet date exchange rates, except for inventories, prepaid expenses, and property, plant, and equipment, which are remeasured at historical rates. Foreign currency income and expenses are remeasured at average exchange rates in effect during the year, except for expenses related to balance sheet amounts which are remeasured at historical exchange rates. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in other income (expense) in the condensed consolidated statements of operations. The financial position and results of operations of the Company’s non-U.S. dollar functional currency subsidiary, Nuvve Denmark, are measured using the subsidiary’s local currency as the functional currency. The Company translates the assets and liabilities of Nuvve Denmark into U.S. dollars using exchange rates in effect at the balance sheet date. Revenues and expenses for the subsidiary are translated using rates that approximate those in effect during the period. The resulting translation gain and loss adjustments are reflected as a foreign currency translation adjustment in accumulated other comprehensive income (loss) within stockholders’ equity in the condensed consolidated balance sheets. Foreign currency translation adjustments are included in other comprehensive income in the condensed consolidated statements of operations and comprehensive loss. (i) Cash and Restricted Cash The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation, which is up to $250,000. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area. Pursuant to the Business Combination agreement, $495,000 of the proceeds received from Newborn’s trust account were required to be set aside in trust for the possible repayment of the Company’s Payroll Protection Plan (“PPP”) loan (Note 7). The Company applied for forgiveness of the PPP loan. In June 2021, the PPP loan was fully forgiven and the $495,000 in trust was released to the Company. In May 2021, in connection with a new office lease agreement, the Company was required to provide an irrevocable, unconditional letter of credit in the amount of $380,000 to the landlord upon execution of the lease. This amount securing the letter of credit was recorded as restricted cash as of June 30, 2021. (j) Accounts Receivable Accounts receivable consist primarily of payments due from customers under the Company’s contracts with customers. The Company performs ongoing credit evaluations of customers to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience with the customer, assessment of their credit history, and review of the invoicing terms of the contract. The Company maintains reserves for potential credit losses on customer accounts when deemed necessary. Based on the analysis the Company did not record an allowance for doubtful accounts as of June 30, 2021 or December 31, 2020. (k) Concentrations of Credit Risk Revenue for customers that accounted for 10% or more of revenue for the three and six months ended June 30, 2021 and 2020, are summarized below: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Customer 1 (grant revenue) 25.7 % * 20.2 % 35.4 % Customer 2 (grant revenue) * 47.6 % 22.9 % * Customer 3 (grant revenue) * 36.0 % * 15.9 % Customer 4 (services revenue) * * * 19.9 % Customer 4 (services revenue) 22.9 % * 13.3 % * Accounts receivable balances for customers that accounted for 10% or more of accounts receivable at June 30, 2021, and December 31, 2020, is summarized below: June 30, December 31, Customer 1 (grant revenue) 12 % 15 % Customer 2 (grant revenue) 22 % 19 % Customer 3 (product revenue) 21 % 27 % Customer 4 (product revenue) * 10 % Customer 5 (product revenue) * 10 % ____________________________ * Amount represents less than 10% (l) Inventories Inventories, consisting primarily of EV charging stations, are stated at the lower of cost or net realizable value. The Company values its inventories using the first-in, first-out method. Cost includes purchased products. Net realizable value is based on current selling prices less costs of disposal. At June 30, 2021, and December 31, 2020, the Company’s inventories consisted solely of finished goods. Should demand for the Company’s products prove to be significantly less than anticipated, the ultimate realizable value of the Company’s inventories could be substantially less than the amount shown on the accompanying condensed consolidated balance sheets. (m) Property and Equipment, Net Property and equipment are carried at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective asset. Maintenance and repairs are expensed as incurred while betterments are capitalized. Upon sale or disposition of assets, any gain or loss is included in the condensed consolidated statement of operations. (n) Intangible Assets Intangible assets consist of patents which are amortized over the period of estimated benefit using the straight-line method. No significant residual value is estimated for intangible assets. (o) Impairment of Long-Lived Assets The Company evaluates long-lived assets, for impairment, including evaluating the useful lives for amortizing intangible assets, whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. There were no such write-downs for the three and six months ended June 30, 2021 and 2020. (p) Investments in Equity Securities Without Readily Determinable Fair Values Investments in equity securities of nonpublic entities without readily determinable fair values are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company reviews its equity securities without readily determinable fair values on a regular basis to determine if the investment is impaired. For purposes of this assessment, the Company considers the investee’s cash position, earnings and revenue outlook, liquidity, and management ownership, among other factors, in its review. If management’s assessment indicates that an impairment exists, the Company estimates the fair value of the equity investment and recognizes in current earnings an impairment loss that is equal to the difference between the fair value of the equity investment and its carrying amount. In February 2019, the Company invested in Dreev SaS, (“Dreev”), a VIE, and determined it was not the primary beneficiary of the VIE (see Note 5). Dreev is a nonpublic entity, for which there is no readily determinable fair value. As of June 30, 2021, and December 31, 2020, the Company’s investment in Dreev was accounted for as an investment in equity securities without a readily determinable fair value. The Company did not recognize an impairment loss on its investment during the three and six months ended June 30, 2021 or the year ended December 31, 2020. (q) Employee Savings Plan The Company maintains a savings plan on behalf of its employees that qualifies under Section 401(k) of the Internal Revenue Code. Participating employees may contribute up to the statutory limits. During the three and six months ended June 30, 2021 and the year ended December 31, 2020, the Company did not contribute to the savings plan. (r) Fair Value Measurement The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued expenses, convertible notes payable, convertible debenture, the conversion option on the notes payable and warrants. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimizes the use of unobservable inputs to the extent possible. The Company also considers counterparty risk and its own credit risk in its assessment of fair value. The categorization of financial instruments within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The inputs used to measure fair value are prioritized based on a three-level hierarchy. The three levels of inputs used to measure fair value are defined as follows: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Other inputs that are observable directly or indirectly, such as quoted prices for similar assets and liabilities or market corroborated inputs. • Level 3 – Unobservable inputs are used when little or no market data is available, which requires the Company to develop its own assumptions about how market participants would value the assets or liabilities. (s) Net Loss Per Share Attributable to Common Stockholders The Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. The dilutive effect of these potential common shares is reflected in diluted earnings per share by application of the treasury stock method. For purposes of this calculation, shares issuable upon the conversion of the Series A Convertible Preferred stock (Note 8), exercise of warrants (Note 8), exercise of the unit purchase option (Note 8), and options to purchase common stock (Note 9) are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive. (t) Revenue Recognition The Company accounts for revenues under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which are generally distinct and accounted for as separate performance obligations. Revenue is recognized net of allowances for credits and any taxes collected from customers, which are subsequently remitted to governmental authorities. The Company determines revenue recognition through the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company’s revenue is primarily derived from sales of EV charging stations, fees for cloud computing services related to providing access to the Company’s GIVe platform, extended warranty and maintenance services. The Company also has performed certain software development services and received government grants. GIVe platform access is considered a monthly series comprising of one performance obligation and fixed fees are recognized as revenue in the period the services are provided to and consumed by the customer. The transaction price for each contract is allocated between the identified performance obligations based on relative estimated standalone selling prices. Products – The Company sells EV charging stations either on a standalone basis or together with services such as access to the GIVe platform, extended warranty and maintenance services. When the charging station is a distinct performance obligation, revenue is recognized upon delivery. For other customer contracts, the charging stations are sold as part of a solution and are not distinct from the services, and revenue from the charging station is recognized upon completion of installation and commissioning of the equipment. Services – Specific contracts contain licenses to the software that provides the V2G functionality for one- to twelve-year contract periods through access to the Company’s software as a service GIVe platform application. The Company determined that the nature of the GIVe application performance obligation is providing continuous access to its GIVe application for the contract period. Although the activities that the customer may be able to perform via the GIVe application may vary from day to day, the overall promise is to provide continuous access to the GIVe application to the customer for a period of one- to twelve-years. Thus, access to the GIVe application represents a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, and the Company has determined that for GIVe SaaS revenue, the best indicator for the transfer of control is the passage of time. The Company has entered into various agreements for research and development and software development services. The terms of these arrangements typically include terms whereby the Company receives milestone payments in accordance with the scope of services outlined in the respective agreement or is reimbursed for allowable costs. At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue associated with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. The Company applies considerable judgment in evaluating factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve a particular milestone in making this assessment. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The Company sells an extended warranty contract on the charging stations, which includes maintenance of the equipment for a period (e.g., three years, five years, 10 years, 12 years). The warranty provides the customer with assurance that the product will function as intended for the period of the contract and maintenance services related to the equipment. Since the warranty provides a customer with a service in addition to the assurance that the product complies with agreed-upon specifications, the promised service is a performance obligation. Access to the warranty services represent a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, and the Company recognizes warranty revenue ratably with the passage of time. Reve |
Revenue Recognition
Revenue Recognition | 6 Months Ended |
Jun. 30, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | Revenue Recognition The disclosures below discuss the Company’s material revenue contracts. The following table provides information regarding disaggregated revenue based on revenue by service lines for the three and six months ended June 30: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue recognized over time: Services $ 363,366 $ 35,739 $ 530,611 $ 296,511 Grants 214,814 408,818 701,943 1,048,427 Products 403,150 18,586 547,808 63,535 Total revenue $ 981,330 $ 463,143 $ 1,780,362 $ 1,408,473 The aggregate amount of revenue for the Company’s existing contracts with customers as of June 30, 2021 expected to be recognized in the future for years ended December 31, is as follows (this disclosure does not include revenue related to contracts whose original expected duration is one year or less): 2021 (remaining six months) $ 379,235 Thereafter 123,133 Total $ 502,368 |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The following are the liabilities measured at fair value on the condensed consolidated balance sheet at June 30, 2021 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): Level 1: Level 2: Level 3: Total at June 30, Total Gains (Losses) For The Three Months Ended June 30, 2021 Total Gains (Losses) For The Six Months Ended June 30, 2021 Recurring fair value measurements Private warrants $ — $ — $ 1,183,000 $ 1,183,000 $ (351,602) $ 70,228 Total recurring fair value measurements $ — $ — $ 1,183,000 $ 1,183,000 $ (351,602) $ 70,228 The following is a reconciliation of the opening and closing balances for the liabilities related to the private warrants (Note 8) measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three and six months ended June 30, 2021: Private Warrants Balance at December 31, 2020 $ — Assumed at closing of merger 1,253,228 Total (gains) losses recognized during the six months ended June 30, 2021 included in earnings (70,228) Balance at June 30, 2021 $ 1,183,000 The fair value of the level 3 Private Warrants was estimated at June 30, 2021 using the Black-Scholes model which used the following inputs: term of 4.7 years, risk free rate of 0.8%, no dividends, volatility of 88.0%, and strike price of $11.50. There were no transfers between Level 1 and Level 2 of the fair value hierarchy in 2021 and 2020. Cash, accounts receivable, accounts payable, and accrued expenses are generally carried on the cost basis, which management believes approximates fair value due to the short-term maturity of these instruments. The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve warrants and securities purchase agreement to purchase shares of the Company’s common stock (see Note 8 for details) at the date of issuance of May 17, 2021: Series B Warrants Series C Warrants Series D Warrants Series E Warrants Series F Warrants Options Fair value (in millions) $12.8 $5.6 $4.8 $3.8 $3.2 $12.6 Valuation methodology Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Black Scholes Terms (years) 10 10 10 10 10 7.50 Risk free rate 1.6% 1.6% 1.6% 1.6% 1.6% 1.4% Strike price $10.0 $15.0 $20.0 $30.0 $40.0 $50.0 Volatility 55.0% 55.0% 55.0% 55.0% 55.0% 57.0% Capital expenditure forecast (in millions) N/A $125.0 $250.0 $375.0 $500.0 N/A Probability of warrants vesting 100.0% 96.9% 87.7% 78.2% 69.9% N/A |
Investment in Dreev
Investment in Dreev | 6 Months Ended |
Jun. 30, 2021 | |
Investments [Abstract] | |
Investment in Dreev | Investment in Dreev In October 2018, the Company entered into a Cooperation Framework Agreement and in February 2019, the Company invested in an enterprise (the “Investment”) with EDF Pulse Croissance Holding (“EDF”), a related party (see Note 12), in which the companies incorporated an entity under the name of Dreev S.A.S., a société par actions simplifiée, organized in France (“Dreev”) in order to jointly develop and market V2G products in France, the UK, Belgium, and Italy (the “G4”). The Company licensed certain of its patents, know-how, and software copyrights (the “IP”) to Dreev to develop and commercialize the IP in the G4, with a promise to transfer the patents to Dreev in the future, in exchange for an initial 49% ownership stake in Dreev. The Company determined that Dreev is a VIE; however, the Company determined that it was not the primary beneficiary of and therefore did not control Dreev. Although the Company did not maintain control over Dreev, it determined it was able to exercise significant influence concerning the Investment. Hence, the Company initially accounted for the Investment on the equity method of accounting. In October 2019, the Company sold 36% of its 49% equity interest in Dreev to EDF. The sale reduced the Company’s equity ownership in Dreev to approximately 13%. Accordingly, the Company discontinued accounting for its investment in Dreev under the equity method at that time, as the Company was no longer able to exercise significant influence over the operations of Dreev. Commencing in October 2018 and continuing through August 2020, the Company performed consulting services to Dreev related to transferring the IP, software development, and operations of Dreev. The consulting services were zero fo r each of the three and six months ended June 30, 2021. The consulting services were $71,643 and $254,212 f or the three and six months ended June 30, 2020, respectively. The consulting services were provided to Dreev at the Company’s cost and is recognized, net of consulting costs, as other income, net in the condensed consolidated statements of operations. |
Intangible Assets
Intangible Assets | 6 Months Ended |
Jun. 30, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Intangible Assets At both June 30, 2021 and December 31, 2020, the Company had recorded a gross intangible asset balance of $2,091,556, which is related to patent and intangible property rights acquired. Amortization expense of intangible assets was $34,860 and $69,719 for the three and six months ended June 30, 2021, respectively. Amortization expense of intangible assets was $26,553 and $53,106 for the three and six months ended June 30, 2020, respectively. Accumulated amortization totaled $540,761 and $471,042 at June 30, 2021 and December 31, 2020, respectively. The net amount of intangible assets of $670,951 at June 30, 2021, will be amortized over the weighted average remaining life of 11.4 years . Total estimated future amortization expense is as follows: 2021 (remaining six months) $ 69,718 2022 139,437 2023 139,437 2024 139,437 2025 139,437 Thereafter 923,329 $ 1,550,795 |
Debt
Debt | 6 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt The following is a summary of debt as of June 30, 2021 and December 31, 2020: June 30, December 31, 6% Senior Secured Convertible Debenture $ — $ 4,000,000 Payroll Protection Plan loan — 492,100 — 4,492,100 Less: discount on convertible debenture — (198,046) Total debt - current $ — $ 4,294,054 6% Senior Secured Convertible Debenture Concurrently with the execution of the Merger Agreement between Nuvve Corp., the Company and Newborn (Note 2), on November 12, 2020, entered into a 6% Senior Secured Convertible Debenture (the “Debenture” or “Bridge Loan”) and a related Securities Purchase Agreement, whereby Nuvve received a loan in the amount of $4,000,000 from a single investor (the “Investor”). The Bridge Loan was funded on November 17, 2020, and the Company received net proceeds of $3,736,435, after deduction of issuance costs of $263,565, which were recorded as debt discount. The maturity date of the Bridge Loan was May 17, 2021. Interest on the Bridge Loan of 6% per annum was due at maturity or conversion of the Note. At the consummation of the Business Combination and the related PIPE financing (Note 2), the principal and interest earned on the Bridge Loan was automatically converted into shares of common stock of the Company based on a conversion price of $1.56, which was exchanged in the Business Combination transaction for shares of the Company. The Debenture was collateralized by all assets of the Company and each Subsidiary pursuant to the Security Agreement, dated as of November 17, 2020 between the Company, the Subsidiaries of the Company and the Investor. Interest expense on the Debenture for the three and six months ended June 30, 2021 is zero and $52,402, r espectively. There was no interest expense on the Debenture for the three and six months ended June 30, 2020. Convertible Notes Payable Beginning in July 2018 and at various dates thereafter, the Company issued convertible notes payable ("Notes"). The Notes accrued interest at 5% per annum. The Notes were due at various dates ranging from January 31, 2019 to December 1, 2021 (Maturity Dates) (if called) or earlier upon the closing of a qualified next equity financing, as defined in the agreement (Next Equity Financing"), or an IPO or liquidation event. In the event of a Next Equity Financing, the Notes balance, including accrued interest, would convert into shares of common or preferred stock issued in connection with the financing, at the lower of a price equal to (a) 80% of the price paid by investors participating in the Next Equity Financing or (b) a fixed dollar amount stated in the Notes contract divided by the fully diluted shares outstanding. In the event of conversion at maturity, a liquidation event or an IPO, the Notes balance, including accrued interest, would be converted to equity securities at a conversion rate based on a fixed dollar amount stated in the Notes contract divided by the fully diluted shares outstanding. On November 17, 2020, the Company entered into the 6% Senior Secured Convertible Debenture, which met the definition of a Next Equity Financing. Accordingly, as of November 17, 2020, the total principal and accrued interest on the Notes then outstanding were converted into a total of 1,529,225 shares of the Company's common stock. As a result, at both June 30, 2021 and December 31, 2020, the outstanding balance on the Notes was zero. The Next Equity Financing conversion options were identified as redemption features for accounting purposes. Accordingly, the redemption feature was bifurcated and recorded at estimated fair value. Since the Notes converted in November 2020, no amounts associated with the redemption feature are reflected in the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020. Interest expense recognized on the Convertible Notes during the three and six months ended June 30, 2021 was zero. Interest expense recognized on the Convertible Notes during the three and six months ended June 30, 2020 was $2,213 and $4,088 , respectively. PPP and EIDL Loans In April 2020, the Company applied for, and in May 2020, the Company received a loan in the amount of $482,100 as a part of the Coronavirus Aid, Relief, and Economic Security ("CARES") Act. The loan is also known as a Payroll Protection Program ("PPP") loan. The loan had a term of 2 years at an interest rate of 1% with principal and interest deferred for 6 months. The loan also was eligible for forgiveness if certain criteria were met. The Company applied for forgiveness of the PPP loan i n June 2021, and it was fully forgiven. Interest expense recognized on the PPP loan for the three and six months ended June 30, 2021 was $402 and $1,607 , respectively. Interest expense recognized on the PPP loan for the three and six months ended June 30, 2020 w as $804 and $804, respectively. |
Stockholders_ Equity
Stockholders’ Equity | 6 Months Ended |
Jun. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Stockholders’ Equity | Stockholders’ Equity As of June 30, 2021, the Company has authorized two classes of stock to be designated, respectively, common stock, and preferred stock. The total number of shares of all classes of capital stock which the Company has authority to issue is 101,000,000, of which 100,000,000 authorized shares are Common Stock with a par value of $0.0001 per share (“Common Stock”), and 1,000,000 authorized shares are Preferred Stock of the par value of $0.0001 per share (“Preferred Stock”). Preferred Stock The Board of Directors is expressly granted authority to issue shares of the Preferred Stock, in one or more series, and to fix for each such series such voting powers, full or limited, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issue of such series (a “Preferred Stock Designation”) and as may be permitted by the General Corporation Law of the State of Delaware. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, without a separate vote of the holders of the Preferred Stock, or any series thereof, unless a vote of any such holders is required pursuant to any Preferred Stock Designation. No preferred stock of Nuvve Holding have been issued and outstanding. Common Stock General : The voting, dividend, liquidation, conversion, and stock split rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Company entitled to vote. Voting : Each holder of Common Stock shall be entitled to one vote for each share of Common Stock held by such holder. Each holder of Common Stock shall be entitled to notice of any stockholders’ meeting in accordance with the Bylaws of the Company (as in effect at the time in question) (the “Bylaws”) and applicable law on all matters put to a vote of the stockholders of the Company. Dividends : Subject to the rights of any holders of any shares of Preferred Stock which may from time to time come into existence and be outstanding, the holders of Common Stock shall be entitled to the payment of dividends when and as declared by the Board of Directors in accordance with applicable law and to receive other distributions from the Company. Any dividends declared by the Board of Directors to the holders of the then outstanding shares of Common Stock shall be paid to the holders thereof pro rata in accordance with the number of shares of Common Stock held by each such holder as of the record date of such dividend. Liquidation : Subject to the rights of any holders of any shares of Preferred Stock which may from time to time come into existence and be outstanding, in the event of any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the funds and assets of the Corporation that may be legally distributed to the Corporation’s stockholders shall be distributed among the holders of the then outstanding shares of Common Stock pro rata in accordance with the number of shares of Common Stock held by each such holder. Warrants - Stonepeak and Evolve On May 17, 2021, in connection with the signing of a letter of agreement relating to the formation of a venture, Levo Mobility LLC, the Company issued to Stonepeak and Evolve a ten years warrants to purchase common stock (allocated 90% to Stonepeak and 10% to Evolve). See Note 15 for details. The grant-date fair value of the warrants issued to Stonepeak and Evolve were; series B $12.8 million, series C $5.6 million, series D $4.8 million, series E $3.8 million and series F $3.2 million. The fair values of the warrants are recorded in the condensed consolidated balance sheet as equity in additional-paid-in capital as it is indexed to the Company’s common stock and meets the conditions for equity classification, and deferred financing costs. Warrants - Public and Private In connection with its initial public offering on February 19, 2020, Newborn sold 5,750,000 units, which included one warrant to purchase Newborn’s common stock (the “Public Warrants”). Also, on February 19, 2020, NeoGenesis Holding Co., Ltd., Newborn’s sponsor (“the Sponsor”), purchased an aggregate of 272,500 private units, each of which included one warrant (the “Private Warrants”), which have the same terms as the Public Warrants. Upon completion of the merger between Nuvve and Newborn, the Public Warrants and Private Warrants were automatically converted to warrants to purchase Common Stock of the Company. Each of the Public Warrants and Private Warrants entitles the holder to purchase one-half of a share of Nuvve’s Common Stock at a price of $11.50 per share. The term of the warrants commenced on March 19, 2021, the date of completion of the Business Combination, and expire on March 19, 2026. The Company may redeem the Public Warrants at a price of $0.01 per warrant upon 30 days’ notice, only in the event that the last sale price of the ordinary shares is at least $16.50 per share for any 20 trading days within a 30-trading day period ending on the third day prior to the date on which notice of redemption is given, provided there is an effective registration statement and current prospectus in effect with respect to the ordinary shares underlying such Warrants during the 30 day redemption period. If the Company decides to redeem the warrants as described above, management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In accordance with the warrant agreement relating to the Public Warrants sold and issued in Newborn’s IPO, the Company is only required to use its best efforts to maintain the effectiveness of the registration statement covering the warrants. If a registration statement is not effective within 90 days following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act of 1933, as amended. In the event that a registration statement is not effective at the time of exercise or no exemption is available for a cashless exercise, the holder of such warrant shall not be entitled to exercise such warrant for cash and in no event (whether in the case of a registration statement being effective or otherwise) will the Company be required to net cash settle the warrant exercise. If an initial Business Combination is not consummated, the Public Warrants will expire and will be worthless. The terms of the Private Warrants are identical to the Public Warrants as described above, except that the Private Warrants are not redeemable so long as they are held by the Sponsor or its permitted transferees. Concurrently with the execution of the Merger Agreement (Note 2), on November 11, 2020, Newborn entered into subscription agreements with certain accredited investors pursuant to which the investors agreed to purchase 1,425,000 of Newborn’s common stock, at a purchase price of $10.00 per share, for an aggregate purchase price of $14,250,000 (the PIPE). Upon closing of the PIPE immediately prior to the closing of the Business Combination (Note 2), the PIPE investors also received 1.9 PIPE Warrants to purchase the Company’s Common Stock for each share of Common Stock purchased. The PIPE Warrants are each exercisable for one-half of a common share at $11.50 per share and have the same terms as described above for the Public Warrants. The PIPE investors received demand and piggyback registration rights in connection with the securities issued to them. The following table is a summary of the number of shares of the Company’s Common Stock issuable upon exercise of warrants outstanding at June 30, 2021 (there were no warrants outstanding at December 31, 2020): Number of Number of Exercise Expiration Public Warrants 2,875,000 — $11.50 March 19, 2026 Private Warrants 136,250 — $11.50 March 19, 2026 PIPE Warrants 1,353,750 — $11.50 March 19, 2026 Stonepeak/Evolve Warrants - series B 2,000,000 — $10.00 May 17, 2031 Stonepeak/Evolve Warrants - series C 1,000,000 — $15.00 May 17, 2031 Stonepeak/Evolve Warrants - series D 1,000,000 — $20.00 May 17, 2031 Stonepeak/Evolve Warrants - series E 1,000,000 — $30.00 May 17, 2031 Stonepeak/Evolve Warrants - series F 1,000,000 — $40.00 May 17, 2031 10,365,000 Because the Private Warrants have dissimilar terms with respect to the Company’s redemption rights depending on the holder of the Private Warrants, the Company determined that the Private Warrants are required to be carried as a liability in the condensed consolidated balance sheet at fair value, with changes in fair value recorded in the condensed consolidated statement of operations. The Private Warrant is reflected as a liability in the condensed consolidated balance sheet as of June 30, 2021 in the amount of $1,183,000 and the change in the fair value of the Private Warrant for the three and six months ended June 30, 2021 of is reflected as loss of $351,602 and a gain of $70,228, respectively, in the condensed consolidated statement of operations. Unit Purchase Option On February 19, 2020, Newborn sold to the underwriters of its initial public offering for $100, a unit purchase option ("UPO") to purchase up to a total of 316,250 units at $11.50 per unit (or an aggregate exercise price of $3,636,875) commencing on the date of Newborn's initial business combination, March 19, 2021, and expiring February 13, 2025. Each unit issuable upon exercise of the UPO consists of one and one-tenth of a share of the Company's common stock and one warrant to purchase one share of the Company's common stock at the exercise price of $11.50 per share. The warrant has the same terms as the Public Warrant. In no event will the Company be required to net cash settle the exercise of the UPO or the warrants underlying the UPO. The holders of the unit purchase option have demand and "piggy back" registration rights for periods of five seven ASC 815-40, Derivatives and Hedging-Contracts in an Entity’s Own Equity, as the UPO is indexed to the Company’s common stock and meets the conditions for equity classification. Put Option On March 19, 2021, the Closing Date of the Business Combination, EDF Renewables exercised its put option on the Company’s common shares held them (see Note 2). As a result, on April 26, 2021, the Company reacquired 134,449 shares of the Company's Common Stock from EDF Renewables for $2,000,000 in cash, at a price per share of approximately $14.87 (the average closing price over the five trading days preceding the date of exercise). Securities Purchase Agreement On May 17, 2021, in connection with the signing of a letter of agreement relating to the formation of a venture, Levo Mobility LLC, the Company entered into a Securities Purchase Agreement with Stonepeak and Evolve which provide them from time to time between November 13, 2021 and November 17, 2028, in their sole discretion, to purchase up to an aggregate of $250 million in shares of the Company’s common stock at a purchase price of $50.00 per share (allocated 90% to Stonepeak and 10% to Evolve). See Note 15 f |
Stock Option Plan
Stock Option Plan | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock Option Plan | Stock Option Plan In 2010, the Company adopted the 2010 Equity Incentive Plan (the “2010 Plan”), which provides for the grant of restricted stock awards, stock options, and other share-based awards to employees, consultants, and directors. In November 2020, the Company’s Board of Directors extended the term of the 2010 Plan to July 1, 2021. In 2021, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which provides for the grant of restricted stock awards, incentive and non-statutory stock options, and other share-based awards to employees, consultants, and directors. As of June 30, 2021, there is an aggregate of 3,300,000 common shares reserved for issuance under the 2020 Plan. All options granted to date have a ten years contractual life and vesting terms of four years. In general, vested options expire if not exercised at termination of service. As of June 30, 2021, a total of 1,258,704 shares of common stock remained available for future issuance under the 2020 Plan. Stock-based compensation expense for the three and six months ended June 30 are as follows Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Options $ 810,738 $ 21,957 $ 1,063,008 $ 32,978 Restricted stock 258,137 — 267,972 — Total $ 1,068,875 $ 21,957 $ 1,330,980 $ 32,978 The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options. Fair value is estimated at the date of grant for employee and nonemployee options. The following assumptions were used in the Black-Scholes model to calculate the fair value of stock options granted for the six months ended June 30, 2021 for the 2010 Plan and the 2020 Plan. 2010 Plan 2020 Plan Expected life of options (in years) (1) 6.0 6.0 Dividend yield (2) 0 % 0 % Risk-free interest rate (3) 1.02 % 1.02 % Volatility (4) 60.4 % 60.4 % __________________ (1) The expected life of options is the average of the contractual term of the options and the vesting period. (2) No cash dividends have been declared on the Company’s common stock since the Company’s inception, and the Company currently does not anticipate declaring or paying cash dividends over the expected life of the options. (3) The risk-free interest rate is based on the yields on U.S. Treasury debt securities with maturities approximating the estimated life of the options. (4) Volatility is estimated by management. As the Company has been a private company for most of its existence, there is not enough historical volatility data related to the Company’s Common stock as a public entity. Therefore, this estimate is based on the average volatility of certain public company peers within the Company’s industry. The following is a summary of the stock option activity under the 2010 Plan, as converted to the Company’s shares due to Reverse Recapitalization, for the six months ended June 30, 2021: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2020 1,235,860 2.89 6.73 — Granted 81,775 8.71 — — Exercised — — — — Forfeited (2,766) 4.41 — — Expired/Cancelled (2,544) 2.73 — — Outstanding - June 30, 2021 1,312,325 3.25 6.39 13,871,041 Options Exercisable at June 30, 2021 974,127 2.03 5.52 11,480,737 Option Vested at June 30, 2021 970,941 2.04 5.51 11,441,071 The weighted-average grant-date fair value of options granted during the six months ended June 30, 2021 was $4.06. The following is a summary of the stock option activity under the 2020 Plan for the six months ended June 30, 2021 : Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2020 — — — — Granted 1,686,350 12.81 9.75 — Exercised — — — — Forfeited — — — — Expired/Cancelled (100) 10.00 — — Outstanding - June 30, 2021 1,686,250 12.81 9.75 1,710,440 Options Exercisable at June 30, 2021 — — — — Option Vested at June 30, 2021 — — — — The weighted-average grant-date fair value of options granted during the six months ended June 30, 2021 was $7.27. During the six months ended June 30, 2021, 1,640,000 options were modified to lower the exercise price by $0.60 per share, which will result in $246,000 of incremental compensation cost to be recognized over the remaining vesting period. The amount of additional compensation expense for the quarter ended June 30, 2021 was $21,728. Other Information: June 30, 2021 Weighted average remaining recognition period Total unrecognized options compensation costs $ 12,504,838 3.56 No amounts relating to the Plan have been capitalized. Compensation cost is recognized over the requisite service period based on the fair value of the options. A summary of the status of the Company’s nonvested restricted stock units as of December 31, 2020, and changes during the six months ended June 30, 2021, is presented below: Shares Weighted- Nonvested at December 31, 2020 — — Granted 355,046 10.81 Vested/Release — — Cancelled/Forfeited — — Nonvested and Outstanding at June 30, 2021 355,046 10.81 As of June 30, 2021, there was $3,568,408 of total unrecognized compensation cost related to nonvested restricted stock. The Company expects to recognize this compensation cost over a remaining weighted-average period of approximately three years. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Income tax (benefit) expense $ 1,000 $ 1,000 $ 1,000 $ 1,000 Effective tax rate 0.0 % (0.1) % 0.0 % (0.1) % The effective tax rate used for interim periods is the estimated annual effective tax rate, based on current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The effective tax rate differed from the U.S. federal statutory tax rate primarily due to operating losses that receive no tax benefit as a result of a valuation allowance recorded for such losses. The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (“ASC 740”). Under the provisions of ASC 740, management is required to evaluate whether a valuation allowance should be established against its deferred tax assets. The Company currently has a full valuation allowance against its deferred tax assets. As of each reporting date, the Company’s management considers new evidence, both positive and negative, that could impact management’s view with regard to future realization of deferred tax assets. For the six months ended June 30, 2021, there was no material change from the year ended December 31, 2020 in the amount of the Company’s deferred tax assets that are not considered to be more likely than not to be realized in future years. On December 27, 2020, the Consolidated Appropriations Act (“CAA”) was enacted in further response to the COVID-19 pandemic, in combination with omnibus spending for the 2021 federal fiscal year. The CAA extended many of the provisions enacted by the CARES Act, which did not have a material impact on the Company’s consolidated financial statements for the year ended December 31, 2020. On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA”) was enacted in still further response to the COVID-19 pandemic. The Company is evaluating the provisions of ARPA but does not expect it to have a material impact on the Company’s consolidated financial statements for the 2021 fiscal year. |
Net Loss Per Share Attributable
Net Loss Per Share Attributable to Common Stockholders | 6 Months Ended |
Jun. 30, 2021 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share Attributable to Common Stockholders | Net Loss Per Share Attributable to Common Stockholders The following table sets forth the calculation of basic and diluted net loss per share attributable to common stockholders during the three and six months ended June 30, 2021 and 2020: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net loss $ (6,187,306) $ (1,054,102) $ (11,549,026) $ (1,551,910) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted 18,668,009 8,778,916 14,560,862 8,778,916 Net Loss per share attributable to common stockholders, basic and diluted $ (0.33) $ (0.12) $ (0.79) $ (0.18) The following outstanding shares of common stock equivalents were excluded from the calculation of the diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Stock options issued and outstanding 2,505,711 962,891 1,792,556 970,387 Nonvested restricted stock issued and outstanding 677,543 — 582,148 — Public warrants 2,875,000 — 1,627,060 — Private warrants 136,250 — 77,109 — PIPE warrants 1,353,750 — 766,133 — Stonepeak and Evolve warrants 2,901,099 — 1,450,549 — Stonepeak and Evolve options 2,417,582 — 1,208,791 — Convertible notes payable — 150,576 — 139,624 Total 12,866,935 1,113,467.00 7,504,346 1,110,011 |
Related Parties
Related Parties | 6 Months Ended |
Jun. 30, 2021 | |
Related Party Transactions [Abstract] | |
Related Parties | Related Parties At March 31, 2020, the Company had accrued compensation payable to an officer and director totaling $471,129. On August 11, 2020, the Board of Directors of the Company approved the conversion of the compensation payable into a convertible note (Note 7). On November 17, 2020, convertible note was converted to common stock (Note 7). As described in Note 5, the Company holds equity interests in and provides certain consulting services to Dreev, an entity in which a stockholder of the Company owns the other portion of Dreev’s equity interests. During 2020, the Company engaged a stockholder for consulting services. During the three and six months ended June 30, 2021 and 2020 no amounts were paid to the stockholder for these services. As of both June 30, 2021 and December 31, 2020, $42,500 due to the stockholder is included in accounts payable in the accompanying condensed consolidated balance sheets. During the three and six months ended June 30, 2021, the Company recognized revenue of $252,000 and $399,620 , respectively. During the three and six months ended June 30, 2020, the Company recognized revenue of zero and $49,501, respectively. The Company had a balance of accounts receivable of $252,000 and zero at June 30, 2021 and December 31, 2020, respectively. The accounts receivable and revenue were from an entity that is an investor in the Company. |
Leases
Leases | 6 Months Ended |
Jun. 30, 2021 | |
Leases [Abstract] | |
Leases | Leases The Company has entered into leases for commercial office spaces and vehicles. These leases are not unilaterally cancellable by the Company, are legally enforceable, and specify fixed or minimum amounts. The leases expire at various dates through 2026 and provide for renewal options. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Also, the agreements generally require the Company to pay real estate taxes, insurance, and repairs. Supplemental unaudited consolidated balance sheet information related to leases is as follows: Classification June 30, 2021 Operating lease assets Right-of-use operating lease assets $ 5,253 Finance lease assets Property, plant and equipment, net 29,977 Total lease assets $ 35,230 Operating lease liabilities - current Operating lease liabilities - current $ 5,406 Finance lease liabilities - current Other liabilities - current 3,363 Finance lease liabilities - noncurrent Other long-term liabilities 26,614 Total lease liabilities $ 35,383 The components of lease expense are as follows: Three Months Ended June 30, Six Months Ended June 30, Classification 2021 2021 Operating lease expense Selling, general and administrative $ 33,396 $ 91,827 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 2,190 2,190 Interest on finance lease liabilities Interest expense 510 510 Total lease expense $ 36,096 $ 94,527 Operating Lease Finance Lease Maturities of lease liabilities are as follows: June 30, 2021 June 30, 2021 2021 $ 5,474 $ 3,977 2022 — 7,954 2023 — 7,954 2024 — 7,954 2025 — 7,954 Thereafter — 1,988 Total lease payments 5,474 37,781 Less: interest (68) (7,804) Total lease obligations $ 5,406 $ 29,977 Lease term and discount rate: June 30, 2021 Weighted-average remaining lease terms (in years): Operating lease 0.2 Finance lease 4.8 Weighted-average discount rate: Operating lease 10% Finance lease 10% Other Information: Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 94,818 Operating cash flows from finance leases 510 Financing cash flows from finance leases $ 1,989 Leased assets obtained in exchange for new finance lease liabilities $ 29,977 Leased assets obtained in exchange for new operating lease liabilities $ — Disclosures related to periods prior to adoption of ASU 2016-02 Rent expenses paid for the year ended December 31, 2020, wa s $334,350. The minimum annual payments under operating leases as of December 31, 2020 through September 2021 was $139,843. Main Office Lease On May 16, 2021, the Company entered into a ten years lease for an additional 10,250 rentable square feet for its main office facilities in San Diego, California. The lease terms include 3% annual fixed increases in the base rental payment. Also, the lease requires the Company to pay operating expenses such as utilities, real estate taxes, insurance, and repairs. The estimated commencement date for the lease is December 1, 2021. The monthly base rent will be abated for the second through and including the eleventh full calendar months of the term and the Company's pro rata share of certain operating expenses will be abated for the first twelve full calendar months of the lease term. The Company was required to provide an irrevocable, unconditional letter of credit in the amount of $380,000 to the landlord upon execution of the lease, and this amount was recorded as restricted cash. The following is a maturity analysis of the annual undiscounted cash flows under the new main office lease for years ended December 31: 2021 $ 41,513 2022 84,270 2023 514,377 2024 529,809 2025 545,703 Thereafter 3,579,935 $ 5,295,607 |
Leases | Leases The Company has entered into leases for commercial office spaces and vehicles. These leases are not unilaterally cancellable by the Company, are legally enforceable, and specify fixed or minimum amounts. The leases expire at various dates through 2026 and provide for renewal options. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Also, the agreements generally require the Company to pay real estate taxes, insurance, and repairs. Supplemental unaudited consolidated balance sheet information related to leases is as follows: Classification June 30, 2021 Operating lease assets Right-of-use operating lease assets $ 5,253 Finance lease assets Property, plant and equipment, net 29,977 Total lease assets $ 35,230 Operating lease liabilities - current Operating lease liabilities - current $ 5,406 Finance lease liabilities - current Other liabilities - current 3,363 Finance lease liabilities - noncurrent Other long-term liabilities 26,614 Total lease liabilities $ 35,383 The components of lease expense are as follows: Three Months Ended June 30, Six Months Ended June 30, Classification 2021 2021 Operating lease expense Selling, general and administrative $ 33,396 $ 91,827 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 2,190 2,190 Interest on finance lease liabilities Interest expense 510 510 Total lease expense $ 36,096 $ 94,527 Operating Lease Finance Lease Maturities of lease liabilities are as follows: June 30, 2021 June 30, 2021 2021 $ 5,474 $ 3,977 2022 — 7,954 2023 — 7,954 2024 — 7,954 2025 — 7,954 Thereafter — 1,988 Total lease payments 5,474 37,781 Less: interest (68) (7,804) Total lease obligations $ 5,406 $ 29,977 Lease term and discount rate: June 30, 2021 Weighted-average remaining lease terms (in years): Operating lease 0.2 Finance lease 4.8 Weighted-average discount rate: Operating lease 10% Finance lease 10% Other Information: Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 94,818 Operating cash flows from finance leases 510 Financing cash flows from finance leases $ 1,989 Leased assets obtained in exchange for new finance lease liabilities $ 29,977 Leased assets obtained in exchange for new operating lease liabilities $ — Disclosures related to periods prior to adoption of ASU 2016-02 Rent expenses paid for the year ended December 31, 2020, wa s $334,350. The minimum annual payments under operating leases as of December 31, 2020 through September 2021 was $139,843. Main Office Lease On May 16, 2021, the Company entered into a ten years lease for an additional 10,250 rentable square feet for its main office facilities in San Diego, California. The lease terms include 3% annual fixed increases in the base rental payment. Also, the lease requires the Company to pay operating expenses such as utilities, real estate taxes, insurance, and repairs. The estimated commencement date for the lease is December 1, 2021. The monthly base rent will be abated for the second through and including the eleventh full calendar months of the term and the Company's pro rata share of certain operating expenses will be abated for the first twelve full calendar months of the lease term. The Company was required to provide an irrevocable, unconditional letter of credit in the amount of $380,000 to the landlord upon execution of the lease, and this amount was recorded as restricted cash. The following is a maturity analysis of the annual undiscounted cash flows under the new main office lease for years ended December 31: 2021 $ 41,513 2022 84,270 2023 514,377 2024 529,809 2025 545,703 Thereafter 3,579,935 $ 5,295,607 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Deferred Compensation The Company has deferred compensation for two of its founders earned during the first five years of the Company's operations, which is payable upon successful completion of a purchase of the Company or an initial public offering. As a result, the Company is committed to pay one of the founders an amount equivalent to 1% of the value of the Company as of the date the Merger transaction closes, which amounted to approximately $1,548,347. The Company is committed to pay the other founder an amount equivalent to 100% of his current base salary at the date the Merger transaction closes, which amounts to approximately 260,000. No deferred compensation amount was accrued at December 31, 2020 related to these commitments as they were contingent upon the successful close of the Merger transaction. The Company accrued $1,808,347 in compensation expense related to these payments during the three months ended March 2021. The deferred compensation was paid to the founders in April 2021. (b) Legal Matters The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including product liability claims. Management believes that any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the financial condition or results of operations of the Company. (c) Research Agreement Effective September 1, 2016, the Company is party to a research agreement with a third party, which is also a Company stockholder, whereby the third party will perform research activity as specified annually by the Company. Under the terms of the agreement, the Company paid a minimum of $400,000 annually in equal quarterly installments. For the six months ended June 30, 2021 and 2020, $200,000 and $166,667 were paid under the research agreement, respectively. At June 30, 2021, $66,667 was outstanding and payable under the agreement. (d) In-Licensing The Company is a party to a licensing agreement for non-exclusive rights to intellectual property which will expire at the later of the date at which the last patent underlying the intellectual property expires or 20 years from the sale of the first licensed product. Under the terms of the agreement, the Company will pay up to an aggregate of $700,000 in royalties upon achievement of certain milestones. As of June 30, 2021 and December 31, 2020, no royalty expenses had been incurred under this agreement . In November 2017, the Company executed an agreement ("IP Acquisition Agreement") with the University of Delaware (Seller) whereby all right, title, and interest in the licensed intellectual property was assigned to the Company in exchange for an upfront fee of $500,000 and common shares valued at $1,491,556. The total acquisition cost of $1,991,556 was capitalized and is being amortized over the fifteen years expected life of the patents underlying the intellectual property. Under the terms of the agreement, the Company will pay up to an aggregate $7,500,000 in royalties to the Seller upon achievement of milestones, related to the aggregate number of vehicles that have had access to the Company’s GIVe platform system for a period of at least six consecutive months, and for which the Company has received monetary consideration for such access pursuant to a subscription or other similar agreement with the vehicle’s owner as follows: Milestone Event: Aggregated Vehicles Milestone 10,000 $ 500,000 20,000 750,000 40,000 750,000 60,000 750,000 80,000 750,000 100,000 1,000,000 200,000 1,000,000 250,000 2,000,000 $ 7,500,000 The Seller will retain a non-exclusive, royalty-free license, to utilize the intellectual property solely for research and education purposes. As of June 30, 2021, no royalty expenses had been incurred under this agreement. (e) Investment The Company is committed to possible future additional contributions to the Investment in Dreev (Note 5) in the amount of $270,000. (f) Reimbursement of Legal Fees On October 5, 2020, the Company entered into an agreement with an investor whereby the Company agreed to reimburse the investor for certain legal fees, up to approximately $96,000 , associated with a license agreement between the parties. The reimbursement is payable upon the completion by the Company of an equity financing or the completion of the licensing agreement. No legal fees have been accrued or paid under this agreement through June 30, 2021. |
Joint Venture
Joint Venture | 6 Months Ended |
Jun. 30, 2021 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Joint Venture | Joint Venture Stonepeak and Evolve Initial Term Sheet On May 17, 2021, the Company entered into a letter agreement (the “Letter Agreement”) with Stonepeak Rocket Holdings LP, a Delaware limited partnership (“Stonepeak”), and Evolve Transition Infrastructure LP, a Delaware limited partnership (“Evolve”), relating to the proposed formation of a venture, Levo Mobility LLC (“Levo,” and such proposed venture, the “Proposed Transaction”). Pursuant to the Letter Agreement, the parties agreed to negotiate in good faith to finalize and enter into definitive agreements for the Proposed Transaction. Under the terms of Proposed Transaction, Levo will utilize the Company’s proprietary V2G technology and the capital from Stonepeak and Evolve to help accelerate the deployment of electric fleets, including zero-emission electric school buses for school districts nationwide through “V2G hubs” and Transportation as a Service (TaaS). If consummated on the proposed terms, Stonepeak and Evolve will fund acquisition and construction costs up to an aggregate capital commitment of $750 million. They will have the option to upsize their capital commitments when Levo has entered into contracts with third parties for $500 million in aggregate capital expenditures. In connection with the signing of the Letter Agreement, the Company issued to Stonepeak and Evolve the following ten years warrants (the “Warrants”) to purchase common stock (allocated 90% to Stonepeak and 10% to Evolve): • Series B warrants to purchase 2,000,000 shares of the Company’s common stock, at an exercise price of $10.00 per share, which are fully vested upon issuance, • Series C warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $15.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $125 million in aggregate capital expenditures, • Series D warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $20.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $250 million in aggregate capital expenditures, • Series E warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $30.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $375 million in aggregate capital expenditures, and • Series F warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $40.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $500 million in aggregate capital expenditures. The warrants may be exercised at any time on or after the date that is 180 days after the applicable vesting date. In connection with the signing of the Letter Agreement, the Company also entered into a Securities Purchase Agreement (the “SPA”) and a Registration Rights Agreement (the “RRA”) with Stonepeak and Evolve. • Under the SPA, from time to time between November 13, 2021 and November 17, 2028, Stonepeak and Evolve may elect, in their sole discretion, to purchase up to an aggregate of $250 million in shares of the Company’s common stock at a purchase price of $50.00 per share (allocated 90% to Stonepeak and 10% to Evolve). The SPA includes customary representations and warranties and closing conditions and customary indemnification provisions. In addition, Stonepeak and Evolve may elect to purchase shares under the SPA on a cashless basis in the event of a change of control of the Company. • Under the RRA, the Company granted Stonepeak and Evolve demand and piggyback registration rights relating to the sale of the Warrants and the shares of the Company’s common stock issuable pursuant to the Warrants and the SPA. The Letter Agreement further requires that the Company use its reasonable best efforts to obtain stockholder approval of the issuance of shares of the Company’s common stock under the Warrants and SPA. On June 30, 2021, the stockholders of the Company, at a special meeting, approved the issuance of shares of the Company’s common stock under the Warrants and SPA. Stonepeak and Evolve Definitive Agreement On August 4, 2021, the Company formed a joint venture, Levo Mobility LLC (“ Levo ,” and such joint venture, the “ Levo Joint V enture”), with Stonepeak Rocket Holdings LP, a Delaware limited partnership (“Stonepeak”), and Evolve Transition Infrastructure LP, a Delaware limited partnership (“Evolve,” and together with Stonepeak, the “Investors”). In connection with the Levo Joint Venture, on August 4, 2021, (the "Joint Venture Date"), the Company’s wholly owned operating subsidiary, Nuvve Corporation (“Nuvve”), Stonepeak and Evolve entered into an Amended and Restated Limited Liability Company Agreement for Levo (the “Levo LLCA”); the Company and Levo entered into a Development Services Agreement (the “DSA”); the Company, Stonepeak, Evolve and Levo entered into a Parent Letter Agreement (the “PLA”); the Company and Stonepeak entered into a Board Rights Agreement (the “BRA”); and the Company and Levo entered into an Intellectual Property License and Escrow Agreement (the “IP License and Escrow Agreement”). The terms of the agreements were substantially consistent the proposed terms set forth in the letter agreement between the parties signed on May 17, 2021. Pursuant to the Levo LLCA, Stonepeak and Evolve plan to make capital contributions to Levo in an aggregate amount of up to $750.0 million (which may be increased up to $1.0 billion) to finance Levo’s business. Levo LLCA The Levo LLCA governs the affairs of Levo and the conduct of its business. The membership interests authorized by the Levo LLCA consist of Class A Common Units, Class B Preferred Units, Class C Common Units and Class D Incentive Units. On the Joint Venture Date and the signing of the Levo LLCA, Levo issued 510,000 Class A Common Units to the Company, 2,801 Class B Preferred Units to Stonepeak and Evolve, and 490,000 Class C Common Units to Stonepeak and Evolve. Stonepeak and Evolve agreed to pay to Levo an aggregate purchase price of $2.8 million for the Class B Preferred Units and the Class C Common Units. Stonepeak and Evolve will receive additional Class B Preferred Units for each $1,000 in additional capital contributions made by them. The Class B Preferred Units have an initial liquidation preference of $1,000 per unit and are entitled to cumulative preferred distributions at a rate of 8.0% of the liquidation preference per annum, payable quarterly. Available cash will be distributed quarterly, first, to the Class B Preferred Unit holders to pay the preferred distributions for such quarter; second, to the Class B Preferred Unit holders to pay all amounts due and unpaid on such units (including accumulated and unpaid preferred distributions); third, until the liquidation preference of the Class B Preferred Units is reduced to $1.0, to the both Class B Preferred Unit holders and the Common Unit holders, with the percentage allocation between them varying based on a leverage ratio; and thereafter, to the Common Unit holders. Distributions on the Class B Preferred Units in excess of the preferred distributions will reduce the liquidation preference of the Class B Preferred Units. Until the completion of the first full twelve fiscal quarters after Stonepeak and Evolve have made aggregate capital contributions of at least $50.0 million, Levo may elect to pay the preferred distributions in cash or in kind. The Class D Incentive Units are profits interests intended to provide incentives to certain key employees and service providers of Levo, its members and its affiliates. The Class D Incentive Unit holders will receive certain distributions from and after the time that the Class B Preferred Unit holders have received a target return on their investment and the Common Unit holders have received a return of their capital contributions. At the earliest to occur of August 4, 2028, a fundamental change (which includes, for example, a change of control of the Company or Nuvve, certain changes in ownership of Levo, a sale of all or substantially all of Levo’s assets, or an initial public offering or direct listing of Levo) (a “Fundamental Change”) or a trigger event (which includes, for example, a failure to pay quarterly distributions or a material breach by us of our obligations under the transaction documents) (a “Trigger Event”), Stonepeak will have the option to cause Levo to redeem the Class B Preferred Units in whole or in part from time to time at a redemption price equal to the greater of the liquidation preference, a price based on a 12.5% internal rate of return, and a price based on a 1.55 multiple on invested capital. At any time following the earliest to occur of August 4, 2028 and a Trigger Event, Stonepeak has the right to cause a sale of Levo. In addition, at any time following the earliest to occur of August 4, 2023, the date on which Levo has entered into contracts with third parties to spend at least $500.0 million in aggregate capital expenditures, and a Trigger Event, Stonepeak has the right to effect an underwritten initial public offering of Levo. Levo will be managed by a board of managers consisting of nine managers, of whom (i) five will be appointed by Nuvve, (ii) for so long as any Class B Preferred Units remain outstanding or Stonepeak owns at least 10.0% or more of the issued and outstanding Common Units, three will be appointed by Stonepeak, and (iii) one will be an independent manager. For so long as Evolve owns more than 2.0% of the issued and outstanding Common Units, Evolve will have the right to designate one person to act as an observer at all meetings of the board of managers, subject to certain limited exceptions. Certain specified actions will require the approval of at least one of the Stonepeak managers, the representative of the Class B Preferred Unit holders and/or Evolve. The Company and its affiliates are required to present to Levo all investment or business opportunities in North America they become aware of and desire to pursue, to the extent such investment or business opportunities are within the scope of, primarily relate to or compete with, Levo’s business, and shall not pursue any such business opportunity, subject to certain exceptions, during the period ending on the earliest to occur of the funding of the full commitment amount (generally $750.0 million, subject to increase or decrease in accordance with the Levo LLCA), the end of the commitment period (generally August 4, 2024, subject to reduction or extension in certain circumstances) or a monetization event (including, for example, an underwritten initial public offering or sale of Levo). The Levo LLCA includes other customary provisions for an agreement of its type, including tag-along rights, a right of first offer on transfers, and drag-along rights. DSA Under the DSA, the Company or one of its affiliates will provide certain services to Levo and its subsidiaries, including operational, commercial, research and development, engineering, business development, legal, regulatory, accounting, treasury, and finance services. As payment for the services, for the initial development period commencing on August 4, 2021 and running through the date that Levo has entered into contracts with third parties to spend at least $25.0 million, in the aggregate, of capital expenditures relating to qualifying business opportunities, Levo will pay the Company an amount equal to 49.0% of its budgeted out-of-pocket and general and administrative expenses allocable to the provision of the services, and a fixed monthly general and administrative fee. After the expiration of the initial development period, Levo will pay the Company an amount equal to 100.0% of its budgeted out-of-pocket and general and administrative expenses allocable to the provision of the services, and a fixed monthly general and administrative fee. The DSA may be terminated under certain conditions, including by Levo for convenience upon 30 days’ written notice, by either party upon written notice to the other party upon a material uncured breach of the DSA, by the Company on 90 days’ written notice if no business opportunities have been approved during the commitment period under the Levo LLCA, or by either party upon 30 days’ notice following the earliest of the 3 rd anniversary of Levo’s initial public offering, the 3 rd anniversary of the date the Comapny ceases to own any Levo equity interests, and the 5 th anniversary of the date the Comapny ceases to have the right to designate a majority of Levo’s board of managers. PLA The PLA includes, among other provisions, certain restrictive covenants with respect to Levo’s business, including a business opportunities covenant applicable to the Company that is identical to the one in the Levo LLCA described above, and a covenant granting Stonepeak a right of first offer to participate in certain future financing transactions of Levo. In addition, the Company agreed to reimburse each of Stonepeak and Evolve for a portion of their out-of-pocket expenses incurred in connection with the due diligence, documentation and negotiation of the agreements. BRA Under the BRA, so long as the Investors beneficially own any Class B Preferred Units or at least 10.0% of the Company’s common stock, Stonepeak has the right to designate two individuals to act as observers at all meetings of the Company’s board of directors. In addition, for so long as the Investors beneficially own at least 10.0% of the Company’s common stock, Stonepeak has the right to designate one individual for appointment as a member of the Company’s board of directors and as a member of one committee of the board of directors (or two committees, if the Investors beneficially own at least 15.0% of the Company’s common stock, or all committees, if the Investors beneficially own at least 25.0% of the Company’s common stock). Any such designee must meet certain qualification requirements. IP License and Escrow Agreement The IP License and Escrow Agreement provides that (i) certain intellectual property of the Company used in Levo’s business will be deposited into escrow, to be released to Levo upon the occurrence of certain specified release events (including, for example, certain circumstances in which the Company ceases to provide the services under the DSA and certain bankruptcy-related events), and (ii) the Company will grant a license to such intellectual property to Levo, which may be exercised solely after the occurrence of one of the specified release events. If (i) one of the specified release events has occurred, (ii) Stonepeak and Evolve have made capital contributions to Levo of at least $1.0 billion in respect of Class B Preferred Units or the commitment period has expired, and (iii) the Company and its subsidiaries no longer own any equity interests in Levo, from and after such time and for so long as the license subsists and the intellectual property remains proprietary, Levo shall pay the Company (or its successor) a royalty on all vehicle-to-grid net revenue generated by or on behalf of or otherwise attributable to Levo and its affiliates and sublicensees from assets acquired or developed by Levo and its sublicensees. The foregoing summaries of the Levo LLCA, the DSA, the BRA and the IP License and Escrow Agreement are qualified in their entirety by reference to the text of such agreements. Please refer to Exhibit 10.17, Exhibit 10.18, Exhibit 10.19, Exhibit 10.20 and Exhibit 10.21 in this Quarterly Report on Form 10-Q for the full text of the agre ements. Reimbursement of Out-of-Pocket Expenses As part of the transaction agreement, the Company is responsible for the first $900,000 of Stonepeak’s out-of-pocket expenses, and the first $100,000 of Evolve’s out-of-pocket expenses. To the extent that the out-of-pocket expenses exceed those levels, Levo would bear all excess amounts. In addition, the Company is responsible for its own Levo related expenses for the first $1.0 million, and expenses above those levels will be borne by Levo. As of June 30, 2021, the Company has incurred and recorded in deferred financing costs $1.0 million towards the responsible for its own Levo related expenses. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On August 4, 2021, the Company formed a joint venture, Levo Mobility LLC with Stonepeak Rocket Holdings LP, a Delaware limited partnership and Evolve Transition Infrastructure LP, a Delaware limited partnership. Please see Note 15 for a summary description of the key items of the joint venture agreement. Also, please refer to Exhibit 10.17, Exhibit 10.18, Exhibit 10.19, Exhibit 10.20 and Exhibit 10.21 in this Quarterly Report on Form 10-Q for the full text of the agreements. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying audited (i) condensed consolidated balance sheet as of December 31, 2020, which has been derived from audited financial statements, and (ii) the unaudited interim condensed financial statements have been prepared in accordance pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Therefore, it is suggested that these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Current Report on Form 8-K dated March 19, 2021, filed with the Securities and Exchange Commission. In the opinion on management, in addition to the adjustments to record the business combination (the “Business Combination”) between Newborn Acquisition Corp (“Newborn”), the Company, and Nuvve Corp., pursuant to which the Company acquired the outstanding shares of Nuvve Corp. (see paragraph below), the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, comprehensive loss, cash flows, and stockholders’ equity for the interim periods, but are not necessarily indicative of the results to be anticipated for the full year 2021 or any future period. The Business Combination between Newborn, a Special Purpose Acquisition Company (“SPAC”), the Company, prior to the Business Combination a wholly owned subsidiary of Newborn, and Nuvve Corp., prior to the Business Combination a privately held operating company, pursuant to which the Company acquired the outstanding shares of Nuvve Corp. (see Business Combination below) was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Newborn was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Nuvve Corp. issuing stock for the net assets of Newborn, accompanied by a recapitalization. The net assets recorded from Newborn are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Nuvve Corp. The shares and corresponding capital amounts and earnings per share available for common stockholders prior to the Business Combination have been retroactively restated to reflect the exchange ratio established in the Business Combination. |
Principles of Consolidation | Principles of ConsolidationThe condensed consolidated financial statements include the accounts and operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation. |
Business Combination | Business Combination The Company is party to a merger agreement (as amended, the “Merger Agreement”), dated as of November 11, 2020 and amended as of February 20, 2021, by and among Newborn, a Cayman Islands company, the Company, a Delaware corporation and prior to the Business Combination a wholly owned subsidiary of Newborn, Nuvve Merger Sub Inc., a Delaware corporation and prior to the Business Combination a wholly-owned subsidiary of the Company (the “Merger Sub”), Nuvve Corp., a Delaware corporation, and Ted Smith, an individual, as the representative of the stockholders of Nuvve Corp. On March 16, 2021, Newborn held an extraordinary general meeting of its shareholders, at which Newborn’s shareholders approved the Business Combination, along with certain other related proposals. On March 19, 2021 (the “Closing Date”), the parties consummated the Business Combination. Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i) Newborn reincorporated to the State of Delaware by merging with and into the Company, with the Company surviving as the publicly-traded entity (the “Reincorporation Merger”); and (ii) immediately after the Reincorporation Merger, Merger Sub merged with and into Nuvve, with Nuvve surviving as a wholly-owned subsidiary of the Company (the “Acquisition Merger”). Immediately prior to the effectiveness of the Reincorporation Merger and the Acquisition Merger, the Company filed its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, pursuant to which, among other things, the Company changed its name to “Nuvve Holding Corp.” and adopted certain other changes that the Company’s Board of Directors deemed appropriate for an operating public company. In connection with the entry into the Merger Agreement, on November 11, 2020, Newborn entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors (the “PIPE Investors”), under which, immediately before the closing of the Business Combination, the PIPE Investors purchased 1,425,000 ordinary shares of Newborn, at a purchase price of $10.00 per share, for an aggregate purchase price of $14,250,000 (the “PIPE”). The PIPE Investors also received warrants to purchase 1,353,750 ordinary shares of Newborn (the “PIPE Warrants”) that were identical to Newborn’s other outstanding warrants. Also, on November 11, 2020, Nuvve Corp. entered into a bridge loan agreement with an accredited investor, under which, on November 17, 2020, the investor purchased a $4,000,000 6% Senior Secured Convertible Debenture from Nuvve Corp. (the “Bridge Loan”), which automatically converted into shares of Nuvve Corp.’s common stock immediately before the closing of the Business Combination. Upon the closing of the Reincorporation Merger, each of Newborn’s outstanding units was automatically separated into its constituent securities, and Newborn’s outstanding securities (including the Newborn ordinary shares and Newborn warrants purchased by the PIPE Investors) were converted into a like number of equivalent securities of the Company, except that each of Newborn’s rights was converted automatically into one-tenth of one share of the Company’s common stock in accordance with its terms. Upon the closing of the Acquisition Merger, each share of Nuvve Corp.’s common stock outstanding immediately prior to the effective time of the Acquisition Merger (including the shares issued upon conversion of Nuvve Corp.’s preferred stock and upon conversion of the Bridge Loan as described above) automatically was converted into approximately 0.212403050 shares (the “Closing Exchange Ratio”) of the Company’s common stock, for an aggregate of 9,122,996 shares of the Company’s common stock. Each outstanding option to purchase Nuvve Corp.’s common stock (“Nuvve Options”) was assumed by the Company and converted into an option to purchase a number of shares of the Company’s common stock equal to the number of shares of Nuvve Corp.’s common stock subject to such option immediately prior to the effective time multiplied by the Closing Exchange Ratio, for an aggregate of 1,303,610 shares of the Company’s common stock, at an exercise price equal to the exercise price immediately prior to the effective time divided by the Closing Exchange Ratio. The Closing Exchange Ratio was determined by taking (i) a number of shares of the Company’s common stock equal to (A) the Closing Merger Consideration (as defined below), divided by (B) $10.00 per share, and dividing it by (ii) the sum of (x) the total number of shares of Nuvve Corp.’s common stock outstanding as of immediately prior to closing (including the shares issued upon conversion of Nuvve Corp.’s preferred stock, but excluding the shares issued upon conversion of the Bridge Loan) and (y) the total number of shares of Nuvve Corp.’s common stock issuable upon exercise of Nuvve Options outstanding immediately prior to the closing. The “Closing Merger Consideration” was determined by taking $100,000,000, subtracting the amount of Nuvve Corp.’s indebtedness for borrowed money as of the closing of the Acquisition Merger (excluding Payroll Protection Program loans eligible for forgiveness – see Note 7), which was zero, and adding the aggregate exercise price of the Nuvve Options outstanding as of the date of the Merger Agreement or granted prior to the closing of the Acquisition Merger, which was $4,265,785. Additionally, the former stockholders of Nuvve Corp. may be entitled to receive up to 4.0 million earn-out shares of the Company’s common stock if, for the fiscal year ending December 31, 2021, the Company’s revenue equals or exceeds $30,000,000. The former Nuvve Corp. stockholders will be entitled to a portion of the earn-out shares only if they continue to hold their shares of the Company’s common stock received in the Acquisition Merger through the earn-out payment date. Pursuant to a purchase and option agreement, dated as of November 11, 2020 (the “Purchase and Option Agreement”), between the Company and EDF Renewables, Inc. (“EDF Renewables”), a former stockholder of Nuvve Corp. and the owner of more than 5% of the Company’s common stock, immediately after the closing, the Company repurchased 600,000 shares of the Company’s common stock from EDF Renewables at a price of $10.00 per share. In addition, on the Closing Date, EDF Renewables exercised its option to sell an additional $2,000,000 of shares of the Company’s common stock back to the Company at a price per share of $14.87 (the average closing price over the five As agreed between the parties to the Merger Agreement, immediately following the closing of the Acquisition Merger, the Company’s board of directors consisted of seven directors, five of whom were designated by Nuvve and two of whom were designated by Newborn. A majority of the directors qualified as independent directors under rules of Nasdaq. In Newborn’s initial public offering, Newborn issued 5,750,000 units at $10.00 per unit. Each unit issued in the initial public offering consisted of one ordinary share, one warrant to purchase one-half of an ordinary share (the “Public Warrant”), and one right automatically convertible into one-tenth of an ordinary upon completion of an initial business combination. Concurrently with the initial public offering, Newborn sold to its sponsor 272,500 units at $10.00 per unit in a private placement. Each unit in the private placement consisted of one ordinary share, one warrant to purchase one-half of an ordinary share (the “Private Warrant”), and one right automatically convertible into one-tenth of an ordinary share upon completion of an initial business combination. Newborn received net proceeds of approximately $57,989,380 from the public and private units. Upon closing of the initial public offering and the private placement, $57,500,000 was placed by Newborn in a trust account with Continental Stock Transfer & Trust Company acting as trustee (the “Trust Account”). On the Closing Date of the Business Combination, the balance in the Trust Account was $58,471,961. After the closing of the Business Combination, and other transactions described above, including payment of $18,630 for redemptions of ordinary shares by Newborn stockholders, payment of transaction costs of $3,702,421, repayment of loans made by Newborn’s sponsor to Newborn of $487,500, repurchase of $6,000,000 in common shares held by EDF Renewables, and transfer into an escrow account with Silicon Valley Bank of $495,000 to cover the balance of the Company’s PPP Loan payable (Note 7), the Company received total net proceeds from the Trust Account in cash of $47,768,410. Also on March 19, 2021, the PIPE closed, and the Company received cash proceeds, net of $2,500 of transaction costs, of $14,247,500. |
Emerging Growth Company | Emerging Growth CompanySection 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits emerging growth companies (“EGC”) to delay complying with new or revised financial accounting standards that do not yet apply to private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act). The Company qualifies as an EGC. The JOBS Act provides that an EGC can elect to opt-out of the extended transition period and comply with the requirements that apply to non-EGCs, but any such election to opt-out is irrevocable. The Company has elected not to opt-out of such an extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This different adoption timing may make a comparison of the Company’s financial statements with another public company which is neither an EGC nor an EGC that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. |
COVID-19 | COVID-19 The novel coronavirus (COVID-19) which was declared a pandemic in March 2020, and the related restrictive measures such as travel restrictions, quarantines, and shutdowns, has negatively impacted the global economy. As national and local governments in different countries ease COVID-19 restrictions, and vaccines are distributed and rolled out successfully, we continue to see improved economic trends. However, COVID-19 and actions taken to mitigate its spread have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. The Company continues to monitor the situation closely but, at this time, is unable to predict the cumulative impact, both in terms of severity and duration, that the coronavirus pandemic has and will have on its business, operating results, cash flows and financial condition, and it could be material if the current circumstances continue to exist for a prolonged period of time. In addition to any direct impact on Nuvve’s business, it is reasonably possible that the estimates made by management in preparing Nuvve’s financial statements have been, or will be, materially and adversely impacted in the near term as a result of the COVID-19 outbreak. |
Use of estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include the impairment of intangible assets, the net realizable value of inventory, the fair value of share-based payments, the fair value of notes payable conversion options, revenue recognition, the fair value of warrants, and the recognition and disclosure of contingent liabilities. Management evaluates its estimates on an ongoing basis. Actual results could materially vary from those estimates. |
Warrants | Warrants The Company reviews the terms of warrants to purchase its common stock to determine whether warrants should be classified as liabilities or stockholders’ equity in its consolidated balance sheet. In order for a warrant to be classified in stockholders’ equity, the warrant must be (a) indexed to the Company’s equity and (b) meet the conditions for equity classification in Accounting Standards Codification (“ASC”) Subtopic 815-40, Derivatives and Hedging – Contracts in an Entity’s Own Equity . If a warrant does not meet the conditions for equity classification, it is carried on the consolidated balance sheet as a warrant liability measured at fair value, with subsequent changes in the fair value of the warrant recorded in the statement of operations as change in fair value of warrants in other income (expense). If a warrant meets both conditions for equity classification, the warrant is initially recorded in additional paid-in capital on the consolidated balance sheet, and the amount initially recorded is not subsequently remeasured at fair value. |
Foreign Currency Matters | Foreign Currency Matters For Nuvve Corp., Nuvve SaS, and Nuvve LTD, the functional currency is the U.S. dollar. All local foreign currency asset and liability amounts are remeasured into U.S. dollars at balance sheet date exchange rates, except for inventories, prepaid expenses, and property, plant, and equipment, which are remeasured at historical rates. Foreign currency income and expenses are remeasured at average exchange rates in effect during the year, except for expenses related to balance sheet amounts which are remeasured at historical exchange rates. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in other income (expense) in the condensed consolidated statements of operations. The financial position and results of operations of the Company’s non-U.S. dollar functional currency subsidiary, Nuvve Denmark, are measured using the subsidiary’s local currency as the functional currency. The Company translates the assets and liabilities of Nuvve Denmark into U.S. dollars using exchange rates in effect at the balance sheet date. Revenues and expenses for the subsidiary are translated using rates that approximate those in effect during the period. The resulting translation gain and loss adjustments are reflected as a foreign currency translation adjustment in accumulated other comprehensive income (loss) within stockholders’ equity in the condensed consolidated balance sheets. Foreign currency translation adjustments are included in other comprehensive income in the condensed consolidated statements of operations and comprehensive loss. |
Cash and Restricted Cash | Cash and Restricted Cash The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation, which is up to $250,000. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area. Pursuant to the Business Combination agreement, $495,000 of the proceeds received from Newborn’s trust account were required to be set aside in trust for the possible repayment of the Company’s Payroll Protection Plan (“PPP”) loan (Note 7). The Company applied for forgiveness of the PPP loan. In June 2021, the PPP loan was fully forgiven and the $495,000 in trust was released to the Company. In May 2021, in connection with a new office lease agreement, the Company was required to provide an irrevocable, unconditional letter of credit in the amount of $380,000 to the landlord upon execution of the lease. This amount securing the letter of credit was recorded as restricted cash as of June 30, 2021. |
Accounts Receivable | Accounts ReceivableAccounts receivable consist primarily of payments due from customers under the Company’s contracts with customers. The Company performs ongoing credit evaluations of customers to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience with the customer, assessment of their credit history, and review of the invoicing terms of the contract. The Company maintains reserves for potential credit losses on customer accounts when deemed necessary. Based on the analysis the Company did not record an allowance for doubtful accounts as of June 30, 2021 or December 31, 2020. |
Concentrations of Credit Risk | Concentrations of Credit Risk Revenue for customers that accounted for 10% or more of revenue for the three and six months ended June 30, 2021 and 2020, are summarized below: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Customer 1 (grant revenue) 25.7 % * 20.2 % 35.4 % Customer 2 (grant revenue) * 47.6 % 22.9 % * Customer 3 (grant revenue) * 36.0 % * 15.9 % Customer 4 (services revenue) * * * 19.9 % Customer 4 (services revenue) 22.9 % * 13.3 % * Accounts receivable balances for customers that accounted for 10% or more of accounts receivable at June 30, 2021, and December 31, 2020, is summarized below: June 30, December 31, Customer 1 (grant revenue) 12 % 15 % Customer 2 (grant revenue) 22 % 19 % Customer 3 (product revenue) 21 % 27 % Customer 4 (product revenue) * 10 % Customer 5 (product revenue) * 10 % ____________________________ |
Inventories | InventoriesInventories, consisting primarily of EV charging stations, are stated at the lower of cost or net realizable value. The Company values its inventories using the first-in, first-out method. Cost includes purchased products. Net realizable value is based on current selling prices less costs of disposal. At June 30, 2021, and December 31, 2020, the Company’s inventories consisted solely of finished goods. Should demand for the Company’s products prove to be significantly less than anticipated, the ultimate realizable value of the Company’s inventories could be substantially less than the amount shown on the accompanying condensed consolidated balance sheets. |
Property and Equipment, Net | Property and Equipment, NetProperty and equipment are carried at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective asset. Maintenance and repairs are expensed as incurred while betterments are capitalized. Upon sale or disposition of assets, any gain or loss is included in the condensed consolidated statement of operations. |
Intangible Assets | Intangible AssetsIntangible assets consist of patents which are amortized over the period of estimated benefit using the straight-line method. No significant residual value is estimated for intangible assets. |
Impairment of Long-Lived Assets | Impairment of Long-Lived AssetsThe Company evaluates long-lived assets, for impairment, including evaluating the useful lives for amortizing intangible assets, whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. There were no such write-downs for the three and six months ended June 30, 2021 and 2020. |
Investments in Equity Securities Without Readily Determinable Fair Values | Investments in Equity Securities Without Readily Determinable Fair Values Investments in equity securities of nonpublic entities without readily determinable fair values are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company reviews its equity securities without readily determinable fair values on a regular basis to determine if the investment is impaired. For purposes of this assessment, the Company considers the investee’s cash position, earnings and revenue outlook, liquidity, and management ownership, among other factors, in its review. If management’s assessment indicates that an impairment exists, the Company estimates the fair value of the equity investment and recognizes in current earnings an impairment loss that is equal to the difference between the fair value of the equity investment and its carrying amount. In February 2019, the Company invested in Dreev SaS, (“Dreev”), a VIE, and determined it was not the primary beneficiary of the VIE (see Note 5). Dreev is a nonpublic entity, for which there is no readily determinable fair value. As of June 30, 2021, and December 31, 2020, the Company’s investment in Dreev was accounted for as an investment in equity securities without a readily determinable fair value. The Company did not recognize an impairment loss on its investment during the three and six months ended June 30, 2021 or the year ended December 31, 2020. |
Employee Savings Plan | Employee Savings PlanThe Company maintains a savings plan on behalf of its employees that qualifies under Section 401(k) of the Internal Revenue Code. Participating employees may contribute up to the statutory limits. During the three and six months ended June 30, 2021 and the year ended December 31, 2020, the Company did not contribute to the savings plan. |
Fair Value Measurement | Fair Value Measurement The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued expenses, convertible notes payable, convertible debenture, the conversion option on the notes payable and warrants. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimizes the use of unobservable inputs to the extent possible. The Company also considers counterparty risk and its own credit risk in its assessment of fair value. The categorization of financial instruments within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The inputs used to measure fair value are prioritized based on a three-level hierarchy. The three levels of inputs used to measure fair value are defined as follows: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Other inputs that are observable directly or indirectly, such as quoted prices for similar assets and liabilities or market corroborated inputs. • Level 3 – Unobservable inputs are used when little or no market data is available, which requires the Company to develop its own assumptions about how market participants would value the assets or liabilities. |
Net Loss Per Share Attributable to Common Stockholders | Net Loss Per Share Attributable to Common StockholdersThe Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. The dilutive effect of these potential common shares is reflected in diluted earnings per share by application of the treasury stock method. For purposes of this calculation, shares issuable upon the conversion of the Series A Convertible Preferred stock (Note 8), exercise of warrants (Note 8), exercise of the unit purchase option (Note 8), and options to purchase common stock (Note 9) are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive. |
Revenue Recognition | Revenue Recognition The Company accounts for revenues under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which are generally distinct and accounted for as separate performance obligations. Revenue is recognized net of allowances for credits and any taxes collected from customers, which are subsequently remitted to governmental authorities. The Company determines revenue recognition through the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company’s revenue is primarily derived from sales of EV charging stations, fees for cloud computing services related to providing access to the Company’s GIVe platform, extended warranty and maintenance services. The Company also has performed certain software development services and received government grants. GIVe platform access is considered a monthly series comprising of one performance obligation and fixed fees are recognized as revenue in the period the services are provided to and consumed by the customer. The transaction price for each contract is allocated between the identified performance obligations based on relative estimated standalone selling prices. Products – The Company sells EV charging stations either on a standalone basis or together with services such as access to the GIVe platform, extended warranty and maintenance services. When the charging station is a distinct performance obligation, revenue is recognized upon delivery. For other customer contracts, the charging stations are sold as part of a solution and are not distinct from the services, and revenue from the charging station is recognized upon completion of installation and commissioning of the equipment. Services – Specific contracts contain licenses to the software that provides the V2G functionality for one- to twelve-year contract periods through access to the Company’s software as a service GIVe platform application. The Company determined that the nature of the GIVe application performance obligation is providing continuous access to its GIVe application for the contract period. Although the activities that the customer may be able to perform via the GIVe application may vary from day to day, the overall promise is to provide continuous access to the GIVe application to the customer for a period of one- to twelve-years. Thus, access to the GIVe application represents a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, and the Company has determined that for GIVe SaaS revenue, the best indicator for the transfer of control is the passage of time. The Company has entered into various agreements for research and development and software development services. The terms of these arrangements typically include terms whereby the Company receives milestone payments in accordance with the scope of services outlined in the respective agreement or is reimbursed for allowable costs. At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue associated with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. The Company applies considerable judgment in evaluating factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve a particular milestone in making this assessment. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The Company sells an extended warranty contract on the charging stations, which includes maintenance of the equipment for a period (e.g., three years, five years, 10 years, 12 years). The warranty provides the customer with assurance that the product will function as intended for the period of the contract and maintenance services related to the equipment. Since the warranty provides a customer with a service in addition to the assurance that the product complies with agreed-upon specifications, the promised service is a performance obligation. Access to the warranty services represent a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, and the Company recognizes warranty revenue ratably with the passage of time. Revenue for other service contracts is recognized over time using an input method where progress on the performance obligation is measured based on the proportion of actual costs incurred to date relative to the total costs expected to be required to satisfy the performance obligation. Grant revenue – The Company has concluded that grants are not within the scope of ASC 606, as government entities do not meet the definition of a “customer” as defined by ASC 606, and as for the grants, there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded these government grants meet the definition of a contribution and are non-reciprocal transactions; however, ASC Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition, does not apply, as the Company is a business entity, and the grants are with a governmental agency. Revenues from each grant are based upon internal costs incurred that are specifically covered by the grant. Revenue is recognized as the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in ASC 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606. The Company considers contract modifications to exist when the modification either creates new or makes changes to the existing enforceable rights and obligations. Contract modifications for services that are not distinct from the existing contract are accounted for as if they were part of that existing contract. In these cases, the effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates are recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract modifications for goods or services that are considered distinct from the existing contract are accounted for as separate contracts. The Company’s contract liabilities consist solely of deferred revenue related to amounts billed or received in advance of services or products delivered. |
Cost of Revenue | Cost of RevenueCost of revenue consists primarily of costs of material, including hardware and software costs, and costs of providing services, including employee compensation and other costs associated with supporting these functions. |
Contract Costs | Contract Costs Under ASC Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers (“ASC 340-40”), the Company defers all incremental costs, including commissions, incurred to obtain the contract and amortizes these costs over the expected period of benefit which is generally the life of the contract. The Company evaluated incremental contract costs for contracts in place as of June 30, 2021, and December 31, 2020 and determined these to be immaterial to the condensed consolidated financial statements. |
Income Taxes | Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, Income Taxes, (“ASC 740”), under which it recognizes deferred income taxes, net of valuation allowances, for net operating losses, tax credit carryforwards, and the estimated future tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. |
Research and Development | Research and DevelopmentThe Company expenses research and development costs as incurred. External software development expense is included in research and development costs except for those costs which require capitalization in accordance with GAAP. Certain research and development costs are related to performance on grant contracts. |
Stock-Based Compensation | Stock-Based Compensation The Company accounts for share-based awards granted to employees and non-employees under the fair value method prescribed by ASC 718-10, Stock Compensation |
Segment Reporting | Segment Reporting The Company operates in a single business segment, which is the EV V2G Charging segment. The following table summarizes the Company’s revenues for the three and six months ended June 30, 2021 and 2020: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenues: United States $ 812,796 $ 272,643 $ 1,404,627 $ 836,559 United Kingdom 113,703 188,436 254,989 319,877 Denmark 54,831 2,064 120,746 252,037 $ 981,330 $ 463,143 $ 1,780,362 $ 1,408,473 The following table summarizes the Company’s long-lived assets in different geographic locations as of June 30, 2021 and December 31, 2020: June 30, December 31, Long-lived assets: United States $ 1,624,203 $ 1,705,201 Denmark 29,977 10,544 $ 1,654,180 $ 1,715,745 |
Recently adopted accounting pronouncements | Recently adopted accounting pronouncements Effective January 1, 2021, the Company adopted the new lease accounting guidance in Accounting Standards Update (“ASU”) No. 2016-2, Leases (Topic 842) using the modified retrospective transition approach. The Company has elected the package of practical expedients permitted in ASC Topic 842 (“ASC 842”). Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease under ASC 842, (b) whether classification of the operating lease would be different in accordance with ASC 842, or (c) whether the unamortized initial direct costs before transition adjustments (as of December 31, 2020) would have met the definition of initial direct costs in ASC 842 at lease commencement. As a result of the adoption of the new lease accounting guidance, as of January 1, 2021 (the date of adoption of ASC 842) the Company recorded (a) a lease liability of $98,491, which represents the present value of the remaining lease payments of $100,292, discounted using the Company’s incremental borrowing rate of 10%, and (b) a right-of-use asset of $95,346, which represents the lease liability of $98,491 adjusted for accrued rent of $3,145. There was no cumulative effect on retained earnings as of January 1, 2021 as a result of adoption of ASC 842. In August 2020, the Financial Accounting Standards Board ("FASB") issued ASU No. 2020-6 , Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-6”) . ASU 2020-6 simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument and more convertible preferred stock as a single equity instrument with no separate accounting for embedded conversion features. ASU 2020-6 also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to be eligible for it. The ASU also simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-6 is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted for annual reporting periods beginning after December 15, 2020. The Company early adopted the provisions of ASU 2020-6 effective January 1, 2021, on the modified retrospective transition method, to take advantage of the removal of certain conditions required for equity contracts to qualify for the derivative scope exception. Adopting ASU 2020-6 did not result in a cumulative impact of adoption during the quarter ended March 31, 2021. |
Recently issued accounting pronouncements not yet adopted | Recently issued accounting pronouncements not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires, among other things, the use of a new current expected credit loss ("CECL") model in determining the allowances for doubtful accounts with respect to accounts receivable, accrued straight-line rents receivable, and notes receivable. The CECL model requires that an entity estimate its lifetime expected credit loss with respect to these receivables and record allowances that, when deducted from the balance of the receivables, represent the net amounts expected to be collected. Entities will also be required to disclose information about how the entity developed the allowances, including changes in the factors that influenced its estimate of expected credit losses and the reasons for those changes. This update is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements. In July 2021, FASB issued Accounting Standards Update (“ASU 2021-05”), Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments . ASU 2021-05 provides that a lessor should classify and account for a lease with variable lease payments that do not depend on an index or a rate as an operating lease if both of the following criteria are met: (1) The lease would’ve been classified as a sales-type lease or a direct-financing lease in accordance with the lease classification guidance in Topic 842, and The lessor would’ve otherwise recognized a day-one loss. The classification as operating would eliminate recognition of a day-one loss or gain because the lessor does not recognize a net investment in the lease or derecognize the underlying asset. ASU 2021-05 align the lessor lease classification requirements under Topic 842 with the longstanding practice to account for certain leases with variable payments as operating leases. ASU 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Schedule of revenue for customers | Revenue for customers that accounted for 10% or more of revenue for the three and six months ended June 30, 2021 and 2020, are summarized below: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Customer 1 (grant revenue) 25.7 % * 20.2 % 35.4 % Customer 2 (grant revenue) * 47.6 % 22.9 % * Customer 3 (grant revenue) * 36.0 % * 15.9 % Customer 4 (services revenue) * * * 19.9 % Customer 4 (services revenue) 22.9 % * 13.3 % * Accounts receivable balances for customers that accounted for 10% or more of accounts receivable at June 30, 2021, and December 31, 2020, is summarized below: June 30, December 31, Customer 1 (grant revenue) 12 % 15 % Customer 2 (grant revenue) 22 % 19 % Customer 3 (product revenue) 21 % 27 % Customer 4 (product revenue) * 10 % Customer 5 (product revenue) * 10 % ____________________________ |
Schedule of company operates in a single business segment | The following table summarizes the Company’s revenues for the three and six months ended June 30, 2021 and 2020: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenues: United States $ 812,796 $ 272,643 $ 1,404,627 $ 836,559 United Kingdom 113,703 188,436 254,989 319,877 Denmark 54,831 2,064 120,746 252,037 $ 981,330 $ 463,143 $ 1,780,362 $ 1,408,473 The following table summarizes the Company’s long-lived assets in different geographic locations as of June 30, 2021 and December 31, 2020: June 30, December 31, Long-lived assets: United States $ 1,624,203 $ 1,705,201 Denmark 29,977 10,544 $ 1,654,180 $ 1,715,745 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of information regarding disaggregated revenue based on revenue by service | The following table provides information regarding disaggregated revenue based on revenue by service lines for the three and six months ended June 30: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue recognized over time: Services $ 363,366 $ 35,739 $ 530,611 $ 296,511 Grants 214,814 408,818 701,943 1,048,427 Products 403,150 18,586 547,808 63,535 Total revenue $ 981,330 $ 463,143 $ 1,780,362 $ 1,408,473 |
Schedule of aggregate amount of revenue for the Company’s existing contracts with customers | The aggregate amount of revenue for the Company’s existing contracts with customers as of June 30, 2021 expected to be recognized in the future for years ended December 31, is as follows (this disclosure does not include revenue related to contracts whose original expected duration is one year or less): 2021 (remaining six months) $ 379,235 Thereafter 123,133 Total $ 502,368 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of liabilities measured at fair value on the condensed consolidated balance sheet | The following are the liabilities measured at fair value on the condensed consolidated balance sheet at June 30, 2021 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): Level 1: Level 2: Level 3: Total at June 30, Total Gains (Losses) For The Three Months Ended June 30, 2021 Total Gains (Losses) For The Six Months Ended June 30, 2021 Recurring fair value measurements Private warrants $ — $ — $ 1,183,000 $ 1,183,000 $ (351,602) $ 70,228 Total recurring fair value measurements $ — $ — $ 1,183,000 $ 1,183,000 $ (351,602) $ 70,228 |
Schedule of fair value on a recurring basis | The following is a reconciliation of the opening and closing balances for the liabilities related to the private warrants (Note 8) measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three and six months ended June 30, 2021: Private Warrants Balance at December 31, 2020 $ — Assumed at closing of merger 1,253,228 Total (gains) losses recognized during the six months ended June 30, 2021 included in earnings (70,228) Balance at June 30, 2021 $ 1,183,000 |
Fair Value Measurement Inputs and Valuation Techniques | The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve warrants and securities purchase agreement to purchase shares of the Company’s common stock (see Note 8 for details) at the date of issuance of May 17, 2021: Series B Warrants Series C Warrants Series D Warrants Series E Warrants Series F Warrants Options Fair value (in millions) $12.8 $5.6 $4.8 $3.8 $3.2 $12.6 Valuation methodology Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Black Scholes Terms (years) 10 10 10 10 10 7.50 Risk free rate 1.6% 1.6% 1.6% 1.6% 1.6% 1.4% Strike price $10.0 $15.0 $20.0 $30.0 $40.0 $50.0 Volatility 55.0% 55.0% 55.0% 55.0% 55.0% 57.0% Capital expenditure forecast (in millions) N/A $125.0 $250.0 $375.0 $500.0 N/A Probability of warrants vesting 100.0% 96.9% 87.7% 78.2% 69.9% N/A |
Intangible Assets (Tables)
Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of estimated future amortization expense amortizable intangible assets | Total estimated future amortization expense is as follows: 2021 (remaining six months) $ 69,718 2022 139,437 2023 139,437 2024 139,437 2025 139,437 Thereafter 923,329 $ 1,550,795 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of debt | The following is a summary of debt as of June 30, 2021 and December 31, 2020: June 30, December 31, 6% Senior Secured Convertible Debenture $ — $ 4,000,000 Payroll Protection Plan loan — 492,100 — 4,492,100 Less: discount on convertible debenture — (198,046) Total debt - current $ — $ 4,294,054 |
Stockholders_ Equity (Tables)
Stockholders’ Equity (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Schedule of common stock issuable upon exercise of warrants outstanding | The following table is a summary of the number of shares of the Company’s Common Stock issuable upon exercise of warrants outstanding at June 30, 2021 (there were no warrants outstanding at December 31, 2020): Number of Number of Exercise Expiration Public Warrants 2,875,000 — $11.50 March 19, 2026 Private Warrants 136,250 — $11.50 March 19, 2026 PIPE Warrants 1,353,750 — $11.50 March 19, 2026 Stonepeak/Evolve Warrants - series B 2,000,000 — $10.00 May 17, 2031 Stonepeak/Evolve Warrants - series C 1,000,000 — $15.00 May 17, 2031 Stonepeak/Evolve Warrants - series D 1,000,000 — $20.00 May 17, 2031 Stonepeak/Evolve Warrants - series E 1,000,000 — $30.00 May 17, 2031 Stonepeak/Evolve Warrants - series F 1,000,000 — $40.00 May 17, 2031 10,365,000 |
Stock Option Plan (Tables)
Stock Option Plan (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of stock-based compensation expense for stock options | Stock-based compensation expense for the three and six months ended June 30 are as follows Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Options $ 810,738 $ 21,957 $ 1,063,008 $ 32,978 Restricted stock 258,137 — 267,972 — Total $ 1,068,875 $ 21,957 $ 1,330,980 $ 32,978 |
Schedule of black-scholes option pricing model to estimate the fair value of stock options | The following assumptions were used in the Black-Scholes model to calculate the fair value of stock options granted for the six months ended June 30, 2021 for the 2010 Plan and the 2020 Plan. 2010 Plan 2020 Plan Expected life of options (in years) (1) 6.0 6.0 Dividend yield (2) 0 % 0 % Risk-free interest rate (3) 1.02 % 1.02 % Volatility (4) 60.4 % 60.4 % __________________ (1) The expected life of options is the average of the contractual term of the options and the vesting period. (2) No cash dividends have been declared on the Company’s common stock since the Company’s inception, and the Company currently does not anticipate declaring or paying cash dividends over the expected life of the options. (3) The risk-free interest rate is based on the yields on U.S. Treasury debt securities with maturities approximating the estimated life of the options. (4) Volatility is estimated by management. As the Company has been a private company for most of its existence, there is not enough historical volatility data related to the Company’s Common stock as a public entity. Therefore, this estimate is based on the average volatility of certain public company peers within the Company’s industry. |
Schedule of stock option activity | The following is a summary of the stock option activity under the 2010 Plan, as converted to the Company’s shares due to Reverse Recapitalization, for the six months ended June 30, 2021: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2020 1,235,860 2.89 6.73 — Granted 81,775 8.71 — — Exercised — — — — Forfeited (2,766) 4.41 — — Expired/Cancelled (2,544) 2.73 — — Outstanding - June 30, 2021 1,312,325 3.25 6.39 13,871,041 Options Exercisable at June 30, 2021 974,127 2.03 5.52 11,480,737 Option Vested at June 30, 2021 970,941 2.04 5.51 11,441,071 The weighted-average grant-date fair value of options granted during the six months ended June 30, 2021 was $4.06. The following is a summary of the stock option activity under the 2020 Plan for the six months ended June 30, 2021 : Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2020 — — — — Granted 1,686,350 12.81 9.75 — Exercised — — — — Forfeited — — — — Expired/Cancelled (100) 10.00 — — Outstanding - June 30, 2021 1,686,250 12.81 9.75 1,710,440 Options Exercisable at June 30, 2021 — — — — Option Vested at June 30, 2021 — — — — |
Disclosure of share-based compensation arrangements by share-based payment award | Other Information: June 30, 2021 Weighted average remaining recognition period Total unrecognized options compensation costs $ 12,504,838 3.56 |
Schedule of nonvested restricted stock units | A summary of the status of the Company’s nonvested restricted stock units as of December 31, 2020, and changes during the six months ended June 30, 2021, is presented below: Shares Weighted- Nonvested at December 31, 2020 — — Granted 355,046 10.81 Vested/Release — — Cancelled/Forfeited — — Nonvested and Outstanding at June 30, 2021 355,046 10.81 |
Income Taxes (Tables)
Income Taxes (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of income tax information | Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Income tax (benefit) expense $ 1,000 $ 1,000 $ 1,000 $ 1,000 Effective tax rate 0.0 % (0.1) % 0.0 % (0.1) % |
Net Loss Per Share Attributab_2
Net Loss Per Share Attributable to Common Stockholders (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of earnings per share | The following table sets forth the calculation of basic and diluted net loss per share attributable to common stockholders during the three and six months ended June 30, 2021 and 2020: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net loss $ (6,187,306) $ (1,054,102) $ (11,549,026) $ (1,551,910) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted 18,668,009 8,778,916 14,560,862 8,778,916 Net Loss per share attributable to common stockholders, basic and diluted $ (0.33) $ (0.12) $ (0.79) $ (0.18) |
Schedule of antidilutive securities excluded from the computation of earnings per share | The following outstanding shares of common stock equivalents were excluded from the calculation of the diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Stock options issued and outstanding 2,505,711 962,891 1,792,556 970,387 Nonvested restricted stock issued and outstanding 677,543 — 582,148 — Public warrants 2,875,000 — 1,627,060 — Private warrants 136,250 — 77,109 — PIPE warrants 1,353,750 — 766,133 — Stonepeak and Evolve warrants 2,901,099 — 1,450,549 — Stonepeak and Evolve options 2,417,582 — 1,208,791 — Convertible notes payable — 150,576 — 139,624 Total 12,866,935 1,113,467.00 7,504,346 1,110,011 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Leases [Abstract] | |
Lease costs | Supplemental unaudited consolidated balance sheet information related to leases is as follows: Classification June 30, 2021 Operating lease assets Right-of-use operating lease assets $ 5,253 Finance lease assets Property, plant and equipment, net 29,977 Total lease assets $ 35,230 Operating lease liabilities - current Operating lease liabilities - current $ 5,406 Finance lease liabilities - current Other liabilities - current 3,363 Finance lease liabilities - noncurrent Other long-term liabilities 26,614 Total lease liabilities $ 35,383 The components of lease expense are as follows: Three Months Ended June 30, Six Months Ended June 30, Classification 2021 2021 Operating lease expense Selling, general and administrative $ 33,396 $ 91,827 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 2,190 2,190 Interest on finance lease liabilities Interest expense 510 510 Total lease expense $ 36,096 $ 94,527 Lease term and discount rate: June 30, 2021 Weighted-average remaining lease terms (in years): Operating lease 0.2 Finance lease 4.8 Weighted-average discount rate: Operating lease 10% Finance lease 10% Other Information: Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 94,818 Operating cash flows from finance leases 510 Financing cash flows from finance leases $ 1,989 Leased assets obtained in exchange for new finance lease liabilities $ 29,977 Leased assets obtained in exchange for new operating lease liabilities $ — |
Lessee, operating lease, liability, maturity | Operating Lease Finance Lease Maturities of lease liabilities are as follows: June 30, 2021 June 30, 2021 2021 $ 5,474 $ 3,977 2022 — 7,954 2023 — 7,954 2024 — 7,954 2025 — 7,954 Thereafter — 1,988 Total lease payments 5,474 37,781 Less: interest (68) (7,804) Total lease obligations $ 5,406 $ 29,977 |
Finance lease, liability, maturity | Operating Lease Finance Lease Maturities of lease liabilities are as follows: June 30, 2021 June 30, 2021 2021 $ 5,474 $ 3,977 2022 — 7,954 2023 — 7,954 2024 — 7,954 2025 — 7,954 Thereafter — 1,988 Total lease payments 5,474 37,781 Less: interest (68) (7,804) Total lease obligations $ 5,406 $ 29,977 |
Schedule of maturity analysis of the annual undiscounted cash flows under the new main office lease | The following is a maturity analysis of the annual undiscounted cash flows under the new main office lease for years ended December 31: 2021 $ 41,513 2022 84,270 2023 514,377 2024 529,809 2025 545,703 Thereafter 3,579,935 $ 5,295,607 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of milestone event | Under the terms of the agreement, the Company will pay up to an aggregate $7,500,000 in royalties to the Seller upon achievement of milestones, related to the aggregate number of vehicles that have had access to the Company’s GIVe platform system for a period of at least six consecutive months, and for which the Company has received monetary consideration for such access pursuant to a subscription or other similar agreement with the vehicle’s owner as follows: Milestone Event: Aggregated Vehicles Milestone 10,000 $ 500,000 20,000 750,000 40,000 750,000 60,000 750,000 80,000 750,000 100,000 1,000,000 200,000 1,000,000 250,000 2,000,000 $ 7,500,000 |
Organization and Description _2
Organization and Description of Business (Details) | 6 Months Ended |
Jun. 30, 2021member | |
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] | |
Company ownership | 100.00% |
Nuvve | |
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] | |
Number of Wholly Owned Subsidiaries | 1 |
Nuvve Corp. | |
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] | |
Number of Wholly Owned Subsidiaries | 3 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Narrative (Details) | Apr. 26, 2021$ / sharesshares | Mar. 19, 2021USD ($)$ / shares | Nov. 17, 2020USD ($) | Nov. 12, 2020 | Nov. 11, 2020USD ($)member$ / sharesshares | Nov. 11, 2020USD ($)member$ / sharesshares | Feb. 19, 2020shares | Mar. 31, 2021USD ($)shares | Mar. 31, 2020shares | Jun. 30, 2021USD ($)$ / sharesshares | Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($)shares | May 17, 2021USD ($)$ / shares | Mar. 18, 2021shares |
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Purchase price (in Dollars per share) | $ / shares | $ 50 | |||||||||||||
Convertible debenture percentage | 6.00% | 6.00% | ||||||||||||
Number of options outstanding (in shares) | shares | 1,303,610 | |||||||||||||
Grant date fair value of securities purchase agreement | $ 12,600,000 | |||||||||||||
Stock repurchased during period (in Shares) | shares | 134,449 | 600,000 | ||||||||||||
Shares issued (in Dollars per share) | $ / shares | $ 10 | $ 10 | ||||||||||||
Stock repurchased, average cost per share (in Dollars per share) | $ / shares | $ 14.87 | $ 14.87 | ||||||||||||
Average closing period | 5 days | 5 days | ||||||||||||
Number of members on the board of directors | member | 7 | 7 | ||||||||||||
Value of amount | $ 2,085,320 | |||||||||||||
Units in values | $ 14,247,500 | |||||||||||||
Value of trust account | $ 58,471,961 | |||||||||||||
Redemption of shares (in Shares) | shares | 18,630 | |||||||||||||
Transaction costs | $ 3,702,421 | |||||||||||||
Repurchase amount | 487,500 | $ 0 | ||||||||||||
Escrow account amount | 495,000 | |||||||||||||
Cash in amount | 47,768,410 | |||||||||||||
FDIC amount | $ 250,000 | |||||||||||||
Warrant description | The Company sells an extended warranty contract on the charging stations, which includes maintenance of the equipment for a period (e.g., three years, five years, 10 years, 12 years). | |||||||||||||
Total lease obligations | $ 5,406 | |||||||||||||
Operating cash flows from operating leases | 94,818 | |||||||||||||
Right-of-use operating assets | 5,253 | $ 0 | ||||||||||||
Operating lease liabilities - current | 5,406 | 0 | ||||||||||||
Subscription Agreements | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Purchased shares (in Shares) | shares | 1,425,000 | |||||||||||||
Purchase price (in Dollars per share) | $ / shares | $ 10 | $ 10 | ||||||||||||
Amount of purchase | $ 14,250,000 | |||||||||||||
Cumulative Effect, Period of Adoption, Adjustment | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Total lease obligations | 98,491 | |||||||||||||
Operating cash flows from operating leases | $ 100,292 | |||||||||||||
Borrowing rate | 10.00% | |||||||||||||
Right-of-use operating assets | $ 95,346 | |||||||||||||
Operating lease liabilities - current | 98,491 | |||||||||||||
Accrued rent | 3,145 | |||||||||||||
EDF Renewables | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Ownership percentage | 5.00% | 5.00% | ||||||||||||
Options to resell common stock to parent, exercised during period, value | $ 2,000,000 | |||||||||||||
Earn-out Shares | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Contingent consideration, revenue threshold | $ 30,000,000 | |||||||||||||
Newborn | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Purchase price (in Dollars per share) | $ / shares | $ 10 | |||||||||||||
Convertible instruments, conversion ratio | 0.212403050 | |||||||||||||
Closing merger consideration, amount used in calculating total consideration | $ 100,000,000 | |||||||||||||
Grant date fair value of securities purchase agreement | 4,265,785 | |||||||||||||
Newborn | Earn-out Shares | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Contingent earnout shares | shares | 4,000,000 | |||||||||||||
6% Senior Secured Convertible Debenture | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Amount of purchase | $ 4,000,000 | |||||||||||||
Convertible debenture percentage | 6.00% | |||||||||||||
PIPE Warrants | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Purchased shares (in Shares) | shares | 1,353,750 | 5,750,000 | ||||||||||||
Common Stock | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Effect of reverse recapitalization (in shares) | shares | 9,122,996 | 8,778,916 | ||||||||||||
Value of amount | $ 21 | |||||||||||||
Units in values | $ 143 | |||||||||||||
Issued shares (in Shares) | shares | 208,532 | |||||||||||||
Repurchase amount | 6,000,000 | |||||||||||||
PIPE Warrants | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Transaction costs | 14,247,500 | |||||||||||||
Cash in amount | $ 2,500 | |||||||||||||
Public and Private units | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Units in values | $ 57,989,380 | |||||||||||||
Newborn | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Stock conversion ratio | 0.1 | |||||||||||||
Issued shares (in Shares) | shares | 57,500,000 | |||||||||||||
Repurchase amount | $ 487,500 | |||||||||||||
Newborn | Private Placement | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Purchased shares (in Shares) | shares | 272,500 | |||||||||||||
Shares issued (in Dollars per share) | $ / shares | $ 10 | |||||||||||||
Number of shares per unit (in Shares) | shares | 1 | |||||||||||||
Number of warrants per unit (in Shares) | shares | 1 | 1 | ||||||||||||
Percent of one share of common stock | 50.00% | |||||||||||||
Number of rights per unit (in Shares) | shares | 1 | |||||||||||||
Percent of common stock issued upon conversion of right | 10.00% | |||||||||||||
Newborn | IPO | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Shares issued (in Dollars per share) | $ / shares | $ 10 | |||||||||||||
Value of amount | $ 5,750,000 | |||||||||||||
Number of shares per unit (in Shares) | shares | 1 | |||||||||||||
Number of warrants per unit (in Shares) | shares | 1 | 1 | ||||||||||||
Percent of one share of common stock | 50.00% | 50.00% | ||||||||||||
Number of rights per unit (in Shares) | shares | 1 | |||||||||||||
Percent of common stock issued upon conversion of right | 10.00% | |||||||||||||
Nuvve | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Number of members on the board of directors | member | 5 | 5 | ||||||||||||
Newborn | ||||||||||||||
Summary of Significant Accounting Policies (Details) [Line Items] | ||||||||||||||
Number of members on the board of directors | member | 2 | 2 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Details) - Schedule of revenue for customers - Customer Concentration Risk | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Customer 1 | Revenue Benchmark | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 25.70% | 20.20% | 35.40% | ||
Customer 1 | Accounts Receivable | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 12.00% | 15.00% | |||
Customer 2 | Revenue Benchmark | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 47.60% | 22.90% | |||
Customer 2 | Accounts Receivable | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 22.00% | 19.00% | |||
Customer 3 | Revenue Benchmark | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 36.00% | 15.90% | |||
Customer 3 | Accounts Receivable | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 21.00% | 27.00% | |||
Customer 4 | Revenue Benchmark | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 22.90% | 13.30% | 19.90% | ||
Customer 4 | Accounts Receivable | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 10.00% | ||||
Customer 5 | Accounts Receivable | |||||
Revenue, Major Customer [Line Items] | |||||
Concentration risk | 10.00% |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies (Details) - Schedule of company operates in a single business segment - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Segment Reporting Information [Line Items] | ||||
Revenues | $ 981,330 | $ 463,143 | $ 1,780,362 | $ 1,408,473 |
Long-lived assets | 1,654,180 | 1,715,745 | 1,654,180 | 1,715,745 |
United States | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 812,796 | 272,643 | 1,404,627 | 836,559 |
Long-lived assets | 1,624,203 | 1,705,201 | 1,624,203 | 1,705,201 |
United Kingdom | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 113,703 | 188,436 | 254,989 | 319,877 |
Denmark | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 54,831 | 2,064 | 120,746 | 252,037 |
Long-lived assets | $ 29,977 | $ 10,544 | $ 29,977 | $ 10,544 |
Revenue Recognition (Details) -
Revenue Recognition (Details) - Schedule of information regarding disaggregated revenue based on revenue by service - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Deferred Revenue Arrangement [Line Items] | ||||
Total revenue | $ 981,330 | $ 463,143 | $ 1,780,362 | $ 1,408,473 |
Services | ||||
Deferred Revenue Arrangement [Line Items] | ||||
Total revenue | 363,366 | 35,739 | 530,611 | 296,511 |
Grants | ||||
Deferred Revenue Arrangement [Line Items] | ||||
Total revenue | 214,814 | 408,818 | 701,943 | 1,048,427 |
Products | ||||
Deferred Revenue Arrangement [Line Items] | ||||
Total revenue | $ 403,150 | $ 18,586 | $ 547,808 | $ 63,535 |
Revenue Recognition (Details)_2
Revenue Recognition (Details) - Schedule of aggregate amount of revenue for the Company’s existing contracts with customers | Jun. 30, 2021USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, amount | $ 502,368 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, amount | $ 379,235 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 6 years |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, amount | $ 123,133 |
Revenue, remaining performance obligation, expected timing of satisfaction, period |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - Schedule of liabilities measured at fair value on the condensed consolidated balance sheet | 3 Months Ended | 6 Months Ended |
Jun. 30, 2021USD ($) | Jun. 30, 2021USD ($) | |
Recurring fair value measurements | ||
Total recurring fair value measurements | $ 1,183,000 | $ 1,183,000 |
Recurring fair value measurements, gain (loss) during period | (351,602) | 70,228 |
Private Warrants | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | 1,183,000 | 1,183,000 |
Recurring fair value measurements, gain (loss) during period | (351,602) | 70,228 |
Level 1: Quoted Prices in Active Markets for Identical Assets | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | 0 | 0 |
Level 1: Quoted Prices in Active Markets for Identical Assets | Private Warrants | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | 0 | 0 |
Level 2: Significant Other Observable Inputs | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | 0 | 0 |
Level 2: Significant Other Observable Inputs | Private Warrants | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | 0 | 0 |
Level 3: Significant Unobservable Inputs | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | 1,183,000 | 1,183,000 |
Level 3: Significant Unobservable Inputs | Private Warrants | ||
Recurring fair value measurements | ||
Total recurring fair value measurements | $ 1,183,000 | $ 1,183,000 |
Fair Value Measurements (Deta_2
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis - Warrants | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Balance | $ 0 |
Assumed at closing of merger | 1,253,228 |
Total (gains) losses for the period included in earnings | (70,228) |
Balance | $ 1,183,000 |
Fair Value Measurements - Narra
Fair Value Measurements - Narrative (Details) | Jun. 30, 2021$ / shares | May 17, 2021 |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants outstanding, term | 10 years | |
Private Warrants | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | $ 11.50 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | $ 11.50 | |
Warrants outstanding, term | 4 years 8 months 12 days | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.008 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.880 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Techniques (Details) | Jun. 30, 2021USD ($)$ / shares | May 17, 2021USD ($)$ / shares |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 1,183,000 | |
Warrants outstanding, term | 10 years | |
Stonepeak/Evolve Warrants - series B | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | $ 10 | |
Stonepeak/Evolve Warrants - series C | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | 15 | |
Stonepeak/Evolve Warrants - series D | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | 20 | |
Stonepeak/Evolve Warrants - series E | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | 30 | |
Stonepeak/Evolve Warrants - series F | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | 40 | |
Private Warrants | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price (in Dollars per share) | $ 11.50 | |
Level 3: Significant Unobservable Inputs | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 1,183,000 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series B | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 12,800,000 | |
Warrants outstanding, term | 10 years | |
Exercise price (in Dollars per share) | $ 10 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series B | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.016 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series B | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.550 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series B | Probability of warrants vesting | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 1 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series C | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 5,600,000 | |
Warrants outstanding, term | 10 years | |
Exercise price (in Dollars per share) | $ 15 | |
Capital expenditure forecast (in millions) | $ | $ 125,000,000 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series C | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.016 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series C | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.550 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series C | Probability of warrants vesting | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.969 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series D | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 4,800,000 | |
Warrants outstanding, term | 10 years | |
Exercise price (in Dollars per share) | $ 20 | |
Capital expenditure forecast (in millions) | $ | $ 250,000,000 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series D | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.016 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series D | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.550 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series D | Probability of warrants vesting | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.877 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series E | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 3,800,000 | |
Warrants outstanding, term | 10 years | |
Exercise price (in Dollars per share) | $ 30 | |
Capital expenditure forecast (in millions) | $ | $ 375,000,000 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series E | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.016 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series E | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.550 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series E | Probability of warrants vesting | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.782 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series F | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 3,200,000 | |
Warrants outstanding, term | 10 years | |
Exercise price (in Dollars per share) | $ 40 | |
Capital expenditure forecast (in millions) | $ | $ 500,000,000 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series F | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.016 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series F | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.550 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak/Evolve Warrants - series F | Probability of warrants vesting | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.699 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak Options | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Fair value (in millions) | $ | $ 12,600,000 | |
Warrants outstanding, term | 7 years 6 months | |
Exercise price (in Dollars per share) | $ 50 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak Options | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.014 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Stonepeak Options | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.570 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants outstanding, term | 4 years 8 months 12 days | |
Exercise price (in Dollars per share) | $ 11.50 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Risk free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.008 | |
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and right outstanding, measurement input | 0.880 |
Investment in Dreev (Details)
Investment in Dreev (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Oct. 31, 2019 | Oct. 31, 2018 | |
Schedule of Investments [Line Items] | ||||||
Company's equity ownership | 13.00% | |||||
Consulting services (in Dollars) | $ 0 | $ 71,643 | $ 0 | $ 254,212 | ||
Dreev | ||||||
Schedule of Investments [Line Items] | ||||||
Company sold equity interest | 49.00% | |||||
Company Sold Equity Interest | Dreev | ||||||
Schedule of Investments [Line Items] | ||||||
Company sold equity interest | 36.00% | |||||
Company's Equity Ownership | ||||||
Schedule of Investments [Line Items] | ||||||
Company's equity ownership | 49.00% |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||||
Gross intangible asset | $ 2,091,556 | $ 2,091,556 | $ 2,091,556 | ||
Amortization expense of intangible assets | 34,860 | $ 26,553 | 69,719 | $ 53,106 | |
Finite-lived intangible assets, accumulated amortization | 540,761 | 540,761 | 471,042 | ||
Finite-lived intangible assets, net | $ 670,951 | $ 670,951 | $ 1,550,795 | ||
Acquire finite-lived intangible assets, weighted average useful life | 11 years 4 months 24 days |
Intangible Assets - Schedule of
Intangible Assets - Schedule of estimated future amortization expense amortizable intangible assets (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2021 (remaining six months) | $ 69,718 | |
2022 | 139,437 | |
2023 | 139,437 | |
2024 | 139,437 | |
2025 | 139,437 | |
Thereafter | 923,329 | |
Total estimated future amortization expense | $ 670,951 | $ 1,550,795 |
Debt - Schedule of debt (Detail
Debt - Schedule of debt (Details) - USD ($) | Nov. 17, 2020 | Nov. 12, 2020 | Jun. 30, 2021 | Dec. 31, 2020 |
Debt Disclosure [Abstract] | ||||
Convertible debenture percentage | 6.00% | 6.00% | ||
6% Senior Secured Convertible Debenture | $ 0 | $ 4,000,000 | ||
Payroll Protection Plan loan | 0 | 492,100 | ||
Total | 0 | 4,492,100 | ||
Less: discount on convertible debenture | $ (263,565) | 0 | (198,046) | |
Total debt - current | $ 0 | $ 4,294,054 |
Debt - Narrative (Details)
Debt - Narrative (Details) - USD ($) | Nov. 17, 2020 | Nov. 12, 2020 | May 31, 2020 | Jul. 30, 2018 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Apr. 30, 2020 | Jul. 31, 2018 |
Debt (Details) [Line Items] | |||||||||||
Convertible debenture percentage | 6.00% | 6.00% | |||||||||
Loan amount | $ 4,000,000 | ||||||||||
Net proceeds | $ 3,736,435 | ||||||||||
Debt discount | $ 263,565 | $ 0 | $ 0 | $ 198,046 | |||||||
Interest percentage | 6.00% | ||||||||||
Conversion price (in Dollars per share) | $ 1.56 | ||||||||||
Interest expense | $ 0 | $ 0 | |||||||||
Debt instrument, stated rate | 5.00% | ||||||||||
Equity financing, conversion price, percent of price paid | 80.00% | ||||||||||
Debt conversion, converted instrument, shares issued | 1,529,225 | ||||||||||
Outstanding balance | 0 | 0 | 0 | ||||||||
Principal amount | 0 | 0 | $ 0 | ||||||||
Coronavirus Aid Relief And Economic Security | |||||||||||
Debt (Details) [Line Items] | |||||||||||
Loan amount | $ 482,100 | ||||||||||
Interest percentage | 1.00% | ||||||||||
Loan term | 2 years | ||||||||||
Debentures Subject to Mandatory Redemption | |||||||||||
Debt (Details) [Line Items] | |||||||||||
Interest expense | 0 | 52,402 | |||||||||
Convertible Notes payable | |||||||||||
Debt (Details) [Line Items] | |||||||||||
Interest expense | 0 | 2,213 | 0 | 4,088 | |||||||
PPP Loan | |||||||||||
Debt (Details) [Line Items] | |||||||||||
Interest expense | $ 402 | 804 | $ 1,607 | 804 | |||||||
Economic Injury Disaster Loan | |||||||||||
Debt (Details) [Line Items] | |||||||||||
Loan amount | $ 149,900 | ||||||||||
Interest expense | $ 0 | $ 0 | |||||||||
Debt instrument, stated rate | 3.75% | ||||||||||
Advance amount | $ 10,000 | ||||||||||
Debt instrument, term | 30 years |
Stockholders_ Equity (Details)
Stockholders’ Equity (Details) | Apr. 26, 2021USD ($)$ / sharesshares | Nov. 11, 2020USD ($)$ / sharesshares | Nov. 11, 2020$ / sharesshares | Feb. 19, 2020USD ($)$ / sharesshares | Jun. 30, 2021USD ($)classOfStock$ / sharesshares | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)classOfStock$ / sharesshares | Jun. 30, 2020USD ($) | May 17, 2021USD ($)$ / shares | Dec. 31, 2020$ / sharesshares |
Stockholders' Equity [Line Items] | ||||||||||
Number of classes of stock | classOfStock | 2 | 2 | ||||||||
Authorized capital stock (in Shares) | shares | 101,000,000 | |||||||||
Common stock, shares authorized (in Shares) | shares | 100,000,000 | 100,000,000 | 30,000,000 | |||||||
Common stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares authorized (in Shares) | shares | 1,000,000 | 1,000,000 | 1,000,000 | |||||||
Preferred stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||
Warrants outstanding, term | 10 years | |||||||||
Redemption period | 30 days | 30 days | ||||||||
Threshold consecutive trading days | 20 days | 20 days | ||||||||
Threshold trading days | 30 days | 30 days | ||||||||
Registration ineffective, threshold trading days | 90 days | 90 days | ||||||||
Purchase price (in Dollars per share) | $ 50 | |||||||||
Fair value (in Dollars) | $ | $ 351,602 | $ 0 | $ (70,228) | $ 0 | ||||||
Shares issued (in Dollars per share) | $ 10 | $ 10 | ||||||||
Stock repurchased during period (in Shares) | shares | 134,449 | 600,000 | ||||||||
Repurchase of common stock from EDF | $ | $ 2,000,000 | 6,000,000 | $ 0 | |||||||
Stock repurchased, average cost per share (in Dollars per share) | $ 14.87 | $ 14.87 | ||||||||
Purchase agreement, authorized amount | $ | $ 250,000,000 | |||||||||
Grant date fair value of securities purchase agreement | $ | $ 12,600,000 | |||||||||
Unit Purchase Option | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Percent of one share of common stock | 10.00% | |||||||||
Shares issued (in Dollars per share) | $ 100 | |||||||||
Exercisable units (in shares) | shares | 316,250 | |||||||||
Options exercisable (in Dollars per share) | $ 11.50 | |||||||||
Aggregate exercise price | $ | $ 3,636,875 | |||||||||
Unit Purchase Option | Minimum | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Right to registration, period | 5 years | |||||||||
Unit Purchase Option | Maximum | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Right to registration, period | 7 years | |||||||||
Investor | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Common stock shares purchase (in Shares) | shares | 1,425,000 | |||||||||
Purchase price per share value (in Dollars per share) | $ 10 | $ 10 | ||||||||
PIPE | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Sale of units (in Shares) | shares | 1.9 | |||||||||
Aggregate purchase price of common stock (in Dollars) | $ | $ 14,250,000 | |||||||||
Purchase price (in Dollars per share) | $ 11.50 | $ 11.50 | ||||||||
Private Placement | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Warrants and rights outstanding | $ | 1,183,000 | 1,183,000 | ||||||||
Fair value (in Dollars) | $ | $ (351,602) | $ 70,228 | ||||||||
Private Placement | Newborn | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Sale of units (in Shares) | shares | 272,500 | |||||||||
Number of warrants per unit (in Shares) | shares | 1 | 1 | ||||||||
Percent of one share of common stock | 50.00% | 50.00% | ||||||||
Shares issued (in Dollars per share) | $ 10 | $ 10 | ||||||||
IPO | Newborn | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Number of warrants per unit (in Shares) | shares | 1 | 1 | ||||||||
Percent of one share of common stock | 50.00% | 50.00% | 50.00% | |||||||
Shares issued (in Dollars per share) | $ 10 | $ 10 | ||||||||
Class of warrant or right, number of securities called by each warrant | shares | 1 | |||||||||
Stonepeak Warrants | Securities Purchase Agreement | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Percent of warrants issued | 90.00% | |||||||||
Evolve Warrants | Securities Purchase Agreement | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Percent of warrants issued | 10.00% | |||||||||
Warrants | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Common stock par value (in Dollars per share) | 11.50 | 11.50 | ||||||||
Sale of units (in Shares) | shares | 1,353,750 | 5,750,000 | ||||||||
Exercise price (in Dollars per share) | 0.01 | 0.01 | ||||||||
Shares, price per share (in Dollars per share) | 16.50 | 16.50 | ||||||||
Warrants | Private Placement | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Aggregate share purchase (in Shares) | shares | 272,500 | |||||||||
Stonepeak/Evolve Warrants - series B | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Warrants outstanding, grant date fair value | $ | $ 12,800,000 | |||||||||
Exercise price (in Dollars per share) | 10 | 10 | ||||||||
Stonepeak/Evolve Warrants - series C | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Warrants outstanding, grant date fair value | $ | 5,600,000 | |||||||||
Exercise price (in Dollars per share) | 15 | 15 | ||||||||
Stonepeak/Evolve Warrants - series D | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Warrants outstanding, grant date fair value | $ | 4,800,000 | |||||||||
Exercise price (in Dollars per share) | 20 | 20 | ||||||||
Stonepeak/Evolve Warrants - series E | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Warrants outstanding, grant date fair value | $ | 3,800,000 | |||||||||
Exercise price (in Dollars per share) | 30 | 30 | ||||||||
Stonepeak/Evolve Warrants - series F | ||||||||||
Stockholders' Equity [Line Items] | ||||||||||
Warrants outstanding, grant date fair value | $ | $ 3,200,000 | |||||||||
Exercise price (in Dollars per share) | $ 40 | $ 40 |
Stockholders_ Equity - Schedule
Stockholders’ Equity - Schedule of common stock issuable upon exercise of warrants outstanding (Details) | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 10,365,000 |
Public Warrants | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 2,875,000 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 11.50 |
Private Warrants | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 136,250 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 11.50 |
PIPE Warrants | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 1,353,750 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 11.50 |
Stonepeak/Evolve Warrants - series B | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 2,000,000 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 10 |
Stonepeak/Evolve Warrants - series C | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 1,000,000 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 15 |
Stonepeak/Evolve Warrants - series D | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 1,000,000 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 20 |
Stonepeak/Evolve Warrants - series E | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 1,000,000 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 30 |
Stonepeak/Evolve Warrants - series F | |
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items] | |
Number of Warrants (in shares) | 1,000,000 |
Number of Warrants Exercisable (in shares) | 0 |
Exercise price (in Dollars per share) | $ / shares | $ 40 |
Stock Option Plan - Narrative (
Stock Option Plan - Narrative (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share based option modified (in Shares) | 1,640,000 | ||
Increase decrease exercise price (in Dollars per share) | $ 0.60 | ||
Incremental compensation cost (in Dollars) | $ 246,000 | ||
Unrecognized compensation costs, period of recognition | 3 years 6 months 21 days | ||
Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Additional compensation expense | $ 21,728 | ||
Restricted stock | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total unrecognized compensation cost related to nonvested restricted stock (in Dollars) | $ 3,568,408 | ||
Unrecognized compensation costs, period of recognition | 3 years | ||
2020 Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Aggregate of common shares (in Shares) | 3,300,000 | 3,300,000 | |
Option contractual life | 10 years | ||
Issuance of common stock available for future (in Shares) | 1,258,704 | 1,258,704 | |
Weighted average grant date fair value of options granted during period (in Dollars per share) | $ 7.27 | ||
2020 Plan | Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Option vesting period | 4 years | ||
2010 Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted average grant date fair value of options granted during period (in Dollars per share) | $ 4.06 |
Stock Option Plan - Schedule of
Stock Option Plan - Schedule of stock-based compensation expense for stock options (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Options | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation | $ 810,738 | $ 21,957 | $ 1,063,008 | $ 32,978 |
Restricted stock | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation | 258,137 | 0 | 267,972 | 0 |
Options and Restricted Stock | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation | $ 1,068,875 | $ 21,957 | $ 1,330,980 | $ 32,978 |
Stock Option Plan - Schedule _2
Stock Option Plan - Schedule of black-scholes option pricing model to estimate the fair value of stock options (Details) | 6 Months Ended |
Jun. 30, 2021 | |
2010 Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected life of options (in years) | 6 years |
Dividend yield | 0.00% |
Risk-free interest rate | 1.02% |
Volatility | 60.40% |
2020 Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected life of options (in years) | 6 years |
Dividend yield | 0.00% |
Risk-free interest rate | 1.02% |
Volatility | 60.40% |
Stock Option Plan - Schedule _3
Stock Option Plan - Schedule of stock option activity (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
2020 Plan | ||
Shares | ||
Beginning balance (in Shares) | 0 | |
Granted, (in Shares) | 1,686,350 | |
Exercised (in Shares) | 0 | |
Forfeited (in Shares) | 0 | |
Expired/Cancelled (in Shares) | (100) | |
Ending balance (in Shares) | 1,686,250 | 0 |
Weighted- Average Exercise Price per Share($) | ||
Beginning balance (in Dollars per share) | $ 0 | |
Granted (in Dollars per share) | 12.81 | |
Exercised (in Dollars per share) | 0 | |
Forfeited (in Dollars per share) | 0 | |
Expired/Cancelled (in Dollars per share) | 10 | |
Ending balance (in Dollars per share) | $ 12.81 | $ 0 |
Weighted- Average Remaining Contractual Term (Years) | ||
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 | 9 years 9 months | |
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 | 9 years 9 months | |
Aggregate Intrinsic Value($) | ||
Outstanding | $ 1,710,440 | |
2010 Plan | ||
Shares | ||
Beginning balance (in Shares) | 1,235,860 | |
Granted, (in Shares) | 81,775 | |
Exercised (in Shares) | 0 | |
Forfeited (in Shares) | (2,766) | |
Expired/Cancelled (in Shares) | (2,544) | |
Ending balance (in Shares) | 1,312,325 | 1,235,860 |
Options exercisable (in Shares) | 974,127 | |
Options vested (in Shares) | 970,941 | |
Weighted- Average Exercise Price per Share($) | ||
Beginning balance (in Dollars per share) | $ 2.89 | |
Granted (in Dollars per share) | 8.71 | |
Exercised (in Dollars per share) | 0 | |
Forfeited (in Dollars per share) | 4.41 | |
Expired/Cancelled (in Dollars per share) | 2.73 | |
Ending balance (in Dollars per share) | 3.25 | $ 2.89 |
Options exercisable (in Dollars per share) | 2.03 | |
Options vested (in Dollars per share) | $ 2.04 | |
Weighted- Average Remaining Contractual Term (Years) | ||
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 | 6 years 4 months 20 days | 6 years 8 months 23 days |
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 | 6 years 4 months 20 days | 6 years 8 months 23 days |
Options exercisable, weighted average remaining contractual term | 5 years 6 months 7 days | |
Options vested, weighted average remaining contractual term | 5 years 6 months 3 days | |
Aggregate Intrinsic Value($) | ||
Outstanding | $ 13,871,041 | |
Exercisable | 11,480,737 | |
Vested | $ 11,441,071 |
Stock Option Plan - Schedule _4
Stock Option Plan - Schedule of other share based compensation information (Details) | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Share-based Payment Arrangement [Abstract] | |
Unrecognized compensation costs | $ 12,504,838 |
Unrecognized compensation costs, period of recognition | 3 years 6 months 21 days |
Stock Option Plan - Schedule _5
Stock Option Plan - Schedule of nonvested restricted stock units (Details) - Restricted Stock Units (RSUs) | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
Beginning balance (in Shares) | shares | 0 |
Granted (in Shares) | shares | 355,046 |
Vested/Release (in Shares) | shares | 0 |
Cancelled/Forfeited (in Shares) | shares | 0 |
Ending balance (in Shares) | shares | 355,046 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |
Beginning balance (in Dollars per share) | $ / shares | $ 0 |
Granted (in Dollars per share) | $ / shares | 10.81 |
Vested/Release (in Dollars per share) | $ / shares | 0 |
Cancelled/Forfeited (in Dollars per share) | $ / shares | 0 |
Ending balance (in Dollars per share) | $ / shares | $ 10.81 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | ||||
Income tax (benefit) expense | $ 1,000 | $ 1,000 | $ 1,000 | $ 1,000 |
Effective tax rate | 0.00% | (0.10%) | 0.00% | (0.10%) |
Net Loss Per Share Attributab_3
Net Loss Per Share Attributable to Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Earnings Per Share [Abstract] | ||||||
Net loss | $ (6,187,306) | $ (5,361,720) | $ (1,054,102) | $ (497,808) | $ (11,549,026) | $ (1,551,910) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares) | 18,668,009 | 8,778,916 | 14,560,862 | 8,778,916 | ||
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares) | 18,668,009 | 8,778,916 | 14,560,862 | 8,778,916 | ||
Net loss per share attributable to common stockholders, basic (in Dollars per share) | $ (0.33) | $ (0.12) | $ (0.79) | $ (0.18) | ||
Net loss per share attributable to common stockholders, diluted (in Dollars per share) | $ (0.33) | $ (0.12) | $ (0.79) | $ (0.18) |
Net Loss Per Share Attributab_4
Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Attributable to common stockholders (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 12,866,935 | 1,113,467 | 7,504,346 | 1,110,011 |
Stock Options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 2,505,711 | 962,891 | 1,792,556 | 970,387 |
Nonvested Restricted Stock | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 677,543 | 0 | 582,148 | 0 |
Public Warrants | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 2,875,000 | 0 | 1,627,060 | 0 |
Private Warrants | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 136,250 | 0 | 77,109 | 0 |
PIPE | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 1,353,750 | 0 | 766,133 | 0 |
Stonepeak Warrants | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 2,901,099 | 0 | 1,450,549 | 0 |
Stonepeak Options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 2,417,582 | 0 | 1,208,791 | 0 |
Convertible Notes payable | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from the computation of earnings per share (in Shares) | 0 | 150,576 | 0 | 139,624 |
Related Parties (Details)
Related Parties (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Mar. 31, 2021 | Dec. 31, 2020 | |
Related Party Transactions [Abstract] | ||||||
Accrued compensation payable | $ 471,129 | |||||
Due to officers and stockholders, current | $ 42,500 | $ 42,500 | $ 42,500 | |||
Revenue from related parties | 252,000 | $ 399,620 | 0 | $ 49,501 | ||
Accounts receivable, related parties | $ 252,000 | $ 252,000 | $ 0 |
Leases - Lease cost (Details)
Leases - Lease cost (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Leases [Abstract] | ||||
Right-of-use operating assets | $ 5,253 | $ 5,253 | $ 0 | |
Finance Lease, Right-of-Use Asset, after Accumulated Amortization | 29,977 | 29,977 | ||
Operating and Finance Lease Right-of-Use Assets | $ 35,230 | $ 35,230 | ||
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] | Property and equipment, net | Property and equipment, net | ||
Operating lease liabilities - current | $ 5,406 | $ 5,406 | $ 0 | |
Finance lease liabilities - current | 3,363 | 3,363 | ||
Finance lease liabilities - noncurrent | 26,614 | 26,614 | ||
Total lease obligations | $ 35,383 | $ 35,383 | ||
Finance lease, liability, current, statement of financial position, extensible list | Other liabilities | Other liabilities | ||
Finance lease, liability, noncurrent, statement of financial position, extensible list | Other long-term liabilities | Other long-term liabilities | ||
Operating lease expense | $ 33,396 | $ 91,827 | ||
Amortization of finance lease assets | 2,190 | $ 2,190 | ||
Interest expense | 510 | $ 510 | ||
Total lease expense | $ 36,096 | $ 94,527 |
Leases - Schedule of operating
Leases - Schedule of operating lease liability maturity (Details) | Jun. 30, 2021USD ($) |
Operating Lease | |
2021 | $ 5,474 |
2022 | 0 |
2023 | 0 |
2024 | 0 |
2025 | 0 |
Thereafter | 0 |
Total lease payments | 5,474 |
Less: interest | (68) |
Total lease obligations | 5,406 |
Finance Lease | |
2021 | 3,977 |
2022 | 7,954 |
2023 | 7,954 |
2024 | 7,954 |
2025 | 7,954 |
Thereafter | 1,988 |
Total lease payments | 37,781 |
Less: interest | (7,804) |
Total lease obligations | $ 29,977 |
Leases - Lease term, discount r
Leases - Lease term, discount rate, and other information (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Weighted-average remaining lease terms (in years): | ||
Operating lease | 2 months 12 days | |
Finance lease | 4 years 9 months 18 days | |
Weighted-average discount rate: | ||
Operating lease | 10.00% | |
Finance lease | 10.00% | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows from operating leases | $ 94,818 | |
Operating cash flows from finance leases | 510 | |
Financing cash flows from finance leases | 1,989 | $ 0 |
Leased assets obtained in exchange for new finance lease liabilities | 29,977 | |
Leased assets obtained in exchange for new operating lease liabilities | $ 0 |
Leases - Narrative (Details)
Leases - Narrative (Details) | 12 Months Ended | ||
Dec. 31, 2020USD ($) | May 31, 2021USD ($) | May 16, 2021ft² | |
Lessee, Lease, Description [Line Items] | |||
Rent expense | $ 334,350 | ||
Total minimum lease payments | 139,843 | ||
Main Office Lease | |||
Lessee, Lease, Description [Line Items] | |||
Total minimum lease payments | $ 5,295,607 | ||
Operating lease, term of contract | 10 years | ||
Net rentable area | ft² | 10,250 | ||
Operating lease, fixed percent increase in rental payment | 3.00% | ||
Letter of credit outstanding | $ 380,000 |
Leases - Schedule of operatin_2
Leases - Schedule of operating liability future minimum payments due (Details) | Dec. 31, 2020USD ($) |
Lessee, Lease, Description [Line Items] | |
Total minimum lease payments | $ 139,843 |
Main Office Lease | |
Lessee, Lease, Description [Line Items] | |
2021 | 41,513 |
2022 | 84,270 |
2023 | 514,377 |
2024 | 529,809 |
2025 | 545,703 |
Thereafter | 3,579,935 |
Total minimum lease payments | $ 5,295,607 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) - USD ($) | Oct. 05, 2020 | Nov. 17, 2017 | Mar. 31, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Sep. 01, 2016 |
Other Commitments [Line Items] | ||||||
Term after company first began operations | 5 years | |||||
Compensation expenses | $ 1,808,347 | |||||
Installment amount | $ 200,000 | $ 166,667 | $ 400,000 | |||
Related party debt outstanding | $ 66,667 | |||||
Property expire | 20 years | |||||
Royalty expense | $ 700,000 | |||||
Royalties payments | 0 | |||||
Acquisition costs, amortization period | 15 years | |||||
Investment | 270,000 | |||||
Legal fees | $ 96,000 | $ 0 | ||||
Founder 1 | ||||||
Other Commitments [Line Items] | ||||||
Deferred compensation liability, percent of company value | 1.00% | |||||
Deferred compensation liability | $ 1,548,347 | |||||
Founder 2 | ||||||
Other Commitments [Line Items] | ||||||
Deferred compensation liability | $ 260,000 | |||||
Deferred compensation liability, percent of salary | 100.00% | |||||
IP Acquisition Agreement | ||||||
Other Commitments [Line Items] | ||||||
Royalties payments | $ 7,500,000 | |||||
Asset acquisition, upfront payment | 500,000 | |||||
Asset acquisition, equity consideration transferred | 1,491,556 | |||||
Asset acquisition, consideration transferred | $ 1,991,556 |
Commitments and Contingencies_2
Commitments and Contingencies - Schedule of milestone event (Details) | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Other Commitments [Line Items] | |
Milestone payment amount | $ 7,500,000 |
10000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 500,000 |
20000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 750,000 |
40000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 750,000 |
60000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 750,000 |
80000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 750,000 |
100000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 1,000,000 |
200000 | |
Other Commitments [Line Items] | |
Milestone payment amount | 1,000,000 |
250000 | |
Other Commitments [Line Items] | |
Milestone payment amount | $ 2,000,000 |
Joint Venture (Details)
Joint Venture (Details) | Aug. 04, 2021USD ($)member$ / sharesshares | May 17, 2021USD ($)$ / sharesshares | Jun. 30, 2021USD ($) | Dec. 31, 2020USD ($) | Nov. 11, 2020member |
Class of Warrant or Right [Line Items] | |||||
Upfront capital commitment | $ 750,000,000 | ||||
Optional amount of additional funding | 500,000,000 | ||||
Purchase agreement, authorized amount | $ 250,000,000 | ||||
Purchase price (in Dollars per share) | $ / shares | $ 50 | ||||
Number of members on the board of directors | member | 7 | ||||
Deferred financing costs | $ 43,818,000 | $ 0 | |||
Levo LLCA | |||||
Class of Warrant or Right [Line Items] | |||||
Transaction related expenses in which the company is responsible | 1,000,000 | ||||
Deferred financing costs | 1,000,000 | ||||
Nuvve | |||||
Class of Warrant or Right [Line Items] | |||||
Number of members on the board of directors | member | 5 | ||||
Subsequent Event | |||||
Class of Warrant or Right [Line Items] | |||||
Capital expenditure forecast (in millions) | $ 750,000,000 | ||||
Class of warrant or right outstanding, potential future capital expenditures | 1,000,000,000 | ||||
Aggregate capital contributions, threshold to determine how distributions shall be paid | $ 50,000,000 | ||||
Triggering event causing redemption, internal rate of return | 12.50% | ||||
Triggering event causing redemption, multiple of invested capital | 1.55 | ||||
Subsequent Event | Class B Preferred Unit | |||||
Class of Warrant or Right [Line Items] | |||||
Liquidation preference per share (in Dollars per share) | $ / shares | $ 1,000 | ||||
Preferred distribution rate | 8.00% | ||||
Distribution preference, liquidation preference per share (in Dollars per share) | $ / shares | $ 1 | ||||
Securities Purchase Agreement | Stonepeak Warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Percent of warrants issued | 90.00% | ||||
Securities Purchase Agreement | Evolve Warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Percent of warrants issued | 10.00% | ||||
Stonepeak | |||||
Class of Warrant or Right [Line Items] | |||||
Out-of-pocket expenses reimbursable | 900,000 | ||||
Evolve | |||||
Class of Warrant or Right [Line Items] | |||||
Out-of-pocket expenses reimbursable | $ 100,000 | ||||
Levo LLCA | Subsequent Event | |||||
Class of Warrant or Right [Line Items] | |||||
Additional capital expenditures, minimum | $ 500,000,000 | ||||
Number of members on the board of directors | member | 9 | ||||
Levo LLCA | Subsequent Event | Development Service Agreement | |||||
Class of Warrant or Right [Line Items] | |||||
Additional capital expenditures, minimum | $ 25,000,000 | ||||
Percent of budgeted out-of-pocket and general and administrative expenses reimbursable | 49.00% | ||||
Percent of reimbursable out-of-pocket and general and administrative expenses after development period | 100.00% | ||||
Levo LLCA | Subsequent Event | Nuvve | |||||
Class of Warrant or Right [Line Items] | |||||
Number of members on the board of directors | member | 5 | ||||
Levo LLCA | Subsequent Event | Stonepeak | |||||
Class of Warrant or Right [Line Items] | |||||
Number of members on the board of directors | member | 3 | ||||
Percent of issued and outstanding units | 10.00% | ||||
Levo LLCA | Subsequent Event | Stonepeak | Board Rights Agreement | Threshold One | |||||
Class of Warrant or Right [Line Items] | |||||
Number of members on the board of directors | member | 1 | ||||
Percent of issued and outstanding units | 10.00% | ||||
Number of observers in board of director meetings | member | 2 | ||||
Number of committees on the board of directors | member | 1 | ||||
Levo LLCA | Subsequent Event | Stonepeak | Board Rights Agreement | Threshold Two | |||||
Class of Warrant or Right [Line Items] | |||||
Percent of issued and outstanding units | 15.00% | ||||
Number of committees on the board of directors | member | 2 | ||||
Levo LLCA | Subsequent Event | Stonepeak | Board Rights Agreement | Threshold Three | |||||
Class of Warrant or Right [Line Items] | |||||
Percent of issued and outstanding units | 25.00% | ||||
Levo LLCA | Subsequent Event | Evolve | |||||
Class of Warrant or Right [Line Items] | |||||
Number of members on the board of directors | member | 1 | ||||
Percent of issued and outstanding units | 2.00% | ||||
Levo LLCA | Subsequent Event | Class A Common Units | |||||
Class of Warrant or Right [Line Items] | |||||
Unit distribution (in Shares) | shares | 510,000 | ||||
Levo LLCA | Subsequent Event | Class B Preferred Unit | |||||
Class of Warrant or Right [Line Items] | |||||
Unit distribution (in Shares) | shares | 2,801 | ||||
Levo LLCA | Subsequent Event | Class C Common Unit | |||||
Class of Warrant or Right [Line Items] | |||||
Unit distribution (in Shares) | shares | 490,000 | ||||
Stonepeak and Evolve | Subsequent Event | Levo LLCA | |||||
Class of Warrant or Right [Line Items] | |||||
Payments to acquire equity units | $ 2,800,000 | ||||
Additional capital contribution to acquire additional units | $ 1,000 | ||||
Stonepeak Warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Percent of warrants issued | 90.00% | ||||
Evolve Warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Percent of warrants issued | 10.00% | ||||
Stonepeak/Evolve Warrants - series B | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | shares | 2,000,000 | ||||
Exercise price (in Dollars per share) | $ / shares | $ 10 | ||||
Stonepeak/Evolve Warrants - series C | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | shares | 1,000,000 | ||||
Exercise price (in Dollars per share) | $ / shares | $ 15 | ||||
Percent of warrants vested upon issuance | 50.00% | ||||
Percent of warrants vested upon additional capital expenditures | 50.00% | ||||
Additional capital expenditure to trigger exercise of nonvested warrants | $ 125,000,000 | ||||
Stonepeak/Evolve Warrants - series D | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | shares | 1,000,000 | ||||
Exercise price (in Dollars per share) | $ / shares | $ 20 | ||||
Percent of warrants vested upon issuance | 50.00% | ||||
Percent of warrants vested upon additional capital expenditures | 50.00% | ||||
Additional capital expenditure to trigger exercise of nonvested warrants | $ 250,000,000 | ||||
Stonepeak/Evolve Warrants - series E | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | shares | 1,000,000 | ||||
Exercise price (in Dollars per share) | $ / shares | $ 30 | ||||
Percent of warrants vested upon issuance | 50.00% | ||||
Percent of warrants vested upon additional capital expenditures | 50.00% | ||||
Additional capital expenditure to trigger exercise of nonvested warrants | $ 375,000,000 | ||||
Stonepeak/Evolve Warrants - series F | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | shares | 1,000,000 | ||||
Exercise price (in Dollars per share) | $ / shares | $ 40 | ||||
Percent of warrants vested upon issuance | 50.00% | ||||
Percent of warrants vested upon additional capital expenditures | 50.00% | ||||
Additional capital expenditure to trigger exercise of nonvested warrants | $ 500,000,000 |